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Few therapeutic alternatives exist for patients with a failing single ventricle 
physiology. To address this need, this thesis project investigated two new therapeutic 
alternatives, which sought to positively augment the Fontan hemodynamics. The first 
modality introduced a non-invasive method of external pressure application to the lower 
extremities. A clinical study (n=2) was conducted, and results indicated an increase in flow 
as a consequence to an increase in transmural pressure in the lower extremities. The second 
modality investigated a minimally invasive blood pump. Numerical analyses of the pump 
xiii 
were performed to examine hydraulic performance under physiologic conditions. The 
pump produced pressure rises of 1 to 25 mmHg over flows of 1 to 4 LPM, has a blood 
damage index less than 1% and was also found to successfully augment the hydraulic 
energy of the Fontan physiology. This work resulted in substantial progress to develop 
both modalities and address a significant human health problem. This document was 
created using Mircosoft Word 2007. 
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CHAPTER 1 MOTIVATION AND SIGNIFICANCE 
 
1.1 Congenital Heart Defects and Diseases 
 
Congenital heart defects are abnormalities with the heart’s structure present at the time 
of birth caused by the incomplete or abnormal development of fetal heart during pregnancy 
[1, 2]. These structural defects involve the interior walls of the heart, heart valves, and 
arteries and veins providing blood perfusion to cardiac tissue. The irregular cardiac 
structure deflects normal blood flow through the heart causing flow to slow down, proceed 
in the incorrect direction or location, or be completely blocked. The severity of defects can 
range from minimal  requiring little to no corrective treatment to complex with life 
threatening symptoms requiring medical and surgical intervention and eventually a heart 
transplant [3, 4]. 
Congenital heart defects are the most common type of birth defect. According to the 
2006 March of Dimes study, each year approximately 8 million children are born 
worldwide with serious, life-threatening heart defects which necessitate corrective surgery 
[5]. The United States alone accounts for about 1 million of these children born with 
congenital heart defects with 40,000 requiring immediate surgical intervention [5,6]. 
Specific conditions include: 
1. Septal Defects – holes in the wall which separates the left side of the heart from the 
right side of the heart allowing mixing of oxygenated and deoxygenated blood. 
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Septal defects can occur in the atria as atrial septal defects (ASD) or in the ventricle 
as ventricular sepatal defects (VSD). In general, a VSD is more severe and can 
require surgical intervention dependent on the magnitude of the defect [6-8].  
2. Valve Defects – structural abnormalities of valves which control blood flow 
throughout the heart and to the body and lungs. Valve defects include (a) stenosis, 
thickening of valve flaps preventing the valve from fully opening, (b) atresia, 
atypical formation of the valve lacking a passage for blood flow, and (c) 
regurgitation, incomplete closure of the valve causing retrograde backflow of 
blood. Common examples of valve defects include aortic stenosis, pulmonary 
stenosis, pulmonary atresia, and tricuspid atresia [6, 8]. 
3. Coarctation of the Aorta (COA) – narrowing of a region within the aorta resulting 
in a significant decrease of blood flow to the lower body [6, 7].  
4. Hypoplastic Left Heart Syndrome - underdeveloped structures of the left, or 
systemic side of the heart causing life threatening inadequate blood flow to the 
body. Within the first few days of the life the baby is diagnosed critically ill and 
requires immediate surgical intervention [2, 6, 7] 
5. Patent Ductus Arteriosus (PDA) – incomplete or no closure of the ductus arteriosus 
(DA) blood vessel which shunts blood away from the lungs redirecting to the body. 
The condition causes excessive blood flow to the newborn’s lungs. PDA commonly 
occurs in premature births [6-8] 
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6. Tetralogy of Fallot (TOF) – complex defect resulting from a combination of four 
heart defects: pulmonary stenosis, VSD, right ventricular hypertrophy, and aortic 
dysfunction receiving blood from both left and right ventricles [6]. 
7. Transposition of the Great Arteries – transposition of the pulmonary artery and 
aorta resulting in delivery of deoxygenated blood from the right ventricle to the 
body and redelivery of oxygenated blood to the lungs from the left ventricle [6, 8] 
 
The most serious and life threatening congenital heart defects are those which involve 
multiple and significant malformations of the heart chambers and vasculature. 
Cardiovascular malformations attribute to 6-10% of all infant deaths [1, 2]. These defects 
represent one of the two leading causes of neonatal death and have an occurrence of 
approximately 1- 8 in 1000 live births with incidence of 1 in 6 infants born preterm [2]. 
Cardiovascular malformations have also been found to contribute to sudden infant death. 
Conditions such as tricuspid artresia and hypoplastic left heart syndrome prompt single 
ventricle anomalies, or the contingency of only one functional ventricle. The only chance 
of survival for these patients is a staged surgical palliation commonly known as Fontan 
completion [4, 9]. 
 
1.2 Fontan Physiology 
 
Clinical interventions prior to the Fontan operative procedure involved aortopulmonary 
shunts and pulmonary artery bands, designed to moderate hypoxemia and congestive heart 
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failure. These interventions, however, cause volume and pressure overloads, often leading 
to chronic ventricular hypertrophy and subendocardial ischemia [10].  
Repair of univentricular physiologies through the Fontan conversion is a staged 
surgical palliation procedure. The first stage, known as the Norwood, occurs within the 
first two weeks of life and provides blood flow to the lungs through a pulmonary arterial 
shunt [11]. Figure 1 illustrates the Norwood repair.   
 
 
Figure 1:  Norwood surgical intervention for 
single ventricle physiologies. A shunt is placed 
between aorta and pulmonary arteries to reduce 
blood oxygen desaturation and promote development 
of the pulmonary vasculature. 
 
 
 
Once the risk of elevated pulmonary vascular resistance in the pulmonary beds has 
decreased the second stage, known as the Glenn, disconnects the Norwood shunt and 
directly connects the superior vena cava (SVC) to pulmonary circulation.  
 
 
Figure 2: Glenn surgical palliative procedure 
providing a direct connection from the superior 
vena cava to pulmonary circulation. The second 
staged surgical palliation, referred to as the Glenn 
procedure, often performed after six weeks and 
directly connects the SVC to the pulmonary 
arteries.  
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The Glenn procedure usually occurs six weeks after birth, followed by the Fontan 
conversion which usually occurs between the ages of 3-5 years, although each patient is 
unique and surgical teams complete the third stage on a case by case basis. Figure 2 shows 
the Glenn surgical configuration. Surgeons may decide, based on the patient’s 
hemodynamics and body response, to remain at the Norwood, Glenn, or Hemi-Fontan 
stage for several years. 
Figure 3: Variations of the Fontan surgical palliation procedure. (A) Intra-Atrial 
Fontan (B) Lateral Tunnel TCPC (C) Extra-Cardiac TCPC[12] 
 
 
The success rate of these high risk procedures is less than 75% [11]. Each patient 
presents a unique challenge to surgical teams resulting in numerous modifications of these 
palliative procedures such as the Hemi-Fontan, Intra-Atrial Fontan, and Extracardiac 
Fontan as a few are demonstrated in Figure 3. The total cavopulmonary connection 
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(TCPC) is an example of the extracardiac Fontan first described by de Leval et al [13]. 
This procedure connects the inferior vena cava (IVC) and superior vena cava (SVC) 
directly to the unbranched right pulmonary artery [10, 14]. TCPC creates a new “man-
made” physiology which entails systemic venous return transmitted directly to pulmonary 
circulation, formulating minimal pulsaltility of flow in pulmonary arteries [10, 15-17]. 
Thus, Fontan circulation is characterized by the absence of a pulmonary ventricle which is 
responsible for driving flow to the lungs. 
Postoperative, these patients suffer from a number of associated complications due to 
their “man-made” physiology.  Of those who survive the three staged palliation, only 85% 
survive the first month, 81% the first year, 79% the first five years, and 71% after 10 years 
[17]. Among the prevalent pathologies an increased after-load on the great veins due to 
elevated pulmonary pressures not only results in a significant reduction of preload reserve, 
but also leads to chronic conditions such as congestive heart failure and diminished 
exercise capacity. Decreased venous return, supraventricular arrhythmias, protein losing 
enteropathy, and aortopullmonary collateral vessels also plague the life-long Fontan 
patients [10, 15, 16, 18]. 
Due to the TCPC, the Fontan patient’s pulmonary perfusion is reliant upon IVC 
pressure, thus systemic pressures are elevated to provide flow. As described by West et al.  
[19] in 1964, the upright lung is classically divided into three regions of characteristic 
alveolar pressure zones secondary to gravitational forces. Each zone is described by 
comparison to arterial and venous pressures. The superior zone demonstrates alveolar 
pressures greater than both arterial and venous pressures, the middle zone with alveolar 
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pressures less than arterial yet greater than venous pressure, and zone 3 with alveolar 
pressure less than both arterial and venous pressure. As can be assumed, zone 3 facilitates 
maximal pulmonary perfusion. Considering their decreased pulmonary vascular 
capacitance and correlated elevated pulmonary vascular resistance, it is likely that Fontan 
patients have a reduced zone 3. 
A recent study performed by Lamour et al. [20] assessed the long term effects of age, 
diagnosis, and previous surgery in both adult and pediatric patients who underwent heart 
transplant for congenital heart disease (CHD). The multi-institutional study merged the 
registries from the Pediatric Heart Transplant Study (PHTS) and Cardiac Transplant 
Research Database (CTRD) to generate a combined dataset of patients receiving a heart 
transplant secondary to CHD. CTRD collected information from patients >18 years of age 
at the time of transplant and PHTS collected from those <18 years of age. Of the 488 CHD 
patients (121 from CTRD and 367 from PHTS) the last major surgical operation performed 
prior to transplant was the Fontan in 22% of patients and Norwood or variants of the Glenn 
in 21% of patients. Post transplant, patients with a previous Fontan had an 8.6-fold 
increase risk of death as compared to all other CHD patients. The survival rates in Fontan 
patients was 71% after the first year and 60% five years post transplant [20]. 
 
1.3 Pediatric Mechanical Circulatory Support 
 
Improved management strategies could reduce the risk of developing late stage, or 
chronic, Fontan induced pathologies [4, 17, 18, 21, 22]. Current research indicates that by 
improving ventricular-vascular interactions, after-load reducing agents can improve Fontan 
8 
hemodynamics [23-26]. Several surgical interventions have been introduced to improve the 
quality of life, increase the time to full cardiac transplant, and raise the overall odds of 
survival [17, 21, 27]. Mechanical circulatory support devices have become an increasingly 
popular treatment option for single ventricular assistance. Historically, preference was 
placed on extracorporeal membrane oxygenation (ECMO) as the fundamental form of 
mechanical circulation in pediatrics. However, efforts have been made towards the use of 
ventricular assist devices (VADs) to extend the time to Fontan failure necessitating full 
cardiac transplantation. Statistically, VADs have been reported as improving the hospital 
survival rate to 89% [9, 27, 28]. Surgical re-interventions to mediate failing Fontans 
include interjection of baffle fenstrations, atrioventricular valve repairs, hepatic vein 
reinclusions, pacemaker placement, prior to full heart transplantation [21]. The incidence 
for ultimate full cardiac transplantation is high, though the waiting time for a donor organ 
can be extensive and the resulting operative mortality rate of 44% [21]. Mechanical 
circulatory support is critical as a bridge-to-transplant, increasing the likelihood of survival 
while waiting for a donor heart.  
 
1.3.1 Extracorporeal Membrane Oxygenation (ECMO) 
 
Extracorporeal membrane oxygenation (ECMO) is the most common resource utilized 
for newborn and pediatric cardiopulmonary support for patients with low refractory cardiac 
output, arrhythmias, cardiac arrest, persistent hypoxemia or inadequate detachment from 
cardiopulmonary bypass [29-33]. Primary use of ECMO is to temporarily replace lung 
function, heat function, or both allowing recovery of a patient’s cardiopulmonary system 
9 
from an acute reversible insult or injury. Numerous studies and patient reports have been 
published reporting the successful use of ECMO as a bridge-to-transplant and bridge-to-
surgical intervention in addition to recovery [27, 30, 34, 35].  The first successful use of 
ECMO for cardio pulmonary bypass was reported in 1975. Since this time, the 
Extracorporeal Life Support Organization, a coalition founded in 1989 to study the clinical 
use of ECMO, has maintained a registry of more than 30,000 patients, a majority of which 
were neonates presenting with respiratory failure [36, 37] . Neonates and newborns present 
with much higher survival rates as compared to pediatric and adult patients. This is 
attributed to the reversibility of the disease and absence of chronic lung and heart 
conditions [38, 39].  
ECMO systems are complex and integrate several mechanical components [28, 39]. A 
sample ECMO circuit from researchers at the Congenital Heart Institute of Florida [35] is 
illustrated in Figure 4.  System components include a roller pump, ECMO bladder, silicone 
membrane or hollow fiber oxygenator, heat exchanger, a centrifugal or roller pump, and IV 
pumps for ultrafiltrate and replacement fluid.  
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Figure 4: Schematic of a typical ECMO loop. ECMO provides hemodynamic and 
pulmonary support.[35] 
 
The accumulation of numerous instruments leads the way to several possible complications 
and creates challenges for patients and hospital staff. An air embolism may form and could 
enter the arterial blood causing systemic embolization. Bubble detectors integrated into the 
system provide early warnings and allow hospital staff to bridge bubbles to the bladder for 
aspiration. Clot formations and plasma protein buildup can occur in the oxygenator 
membrane reducing the surface contact area for blood and gas. Additional technical 
failures include oxygenator failure, failure of heat exchanger, pump failure, and tube 
rupture [34, 35, 40].  
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Heparin must be continuously infused to maintain ACT between 180 to 220 seconds 
with calcium added to reverse CPD-A anticoagulation effects [30]. Heparin excretion is 
part metabolized and part intact in urine, therefore urine production has a considerable 
effect on apparent heparin utilization rate. The half-life of heparin in neonates on ECMO is 
45 to 70 minutes. Heparin levels must be checked every morning by performing a heparin 
assay. Side effects from heparin include intracranial bleeding and bleeding at the cannula 
site [30, 41, 42].  
 Patients on ECMO are immobile and must remain under supervision due to the 
bulky complex system and propensity of complications. Average time for extubation is 24 
to 48 hours and supplemental oxygen is required for the first week [40, 43, 44].  Though 
the oxygenator, coating material of the circuit internal surface, and blood flow controller in 
ECMO systems have been refined and modernized since the systems first introduction in 
the late 1970s,  survival rates post hospital discharge in pediatric patients is approximately 
50% [30, 35, 45-47] . Single ventricle physiologies have been hypothesized as one cause 
for high mortality rates [30, 34]. 
 
1.3.2 Ventricular Assist Devices (VADs) 
 
While many heart pumps or ventricular assist devices (VADs) are being developed 
and in various stages of clinical testing, all of these blood pumps generate pressures in far 
excess of the desired range for cavopulmonary support. Progress in the development of 
pediatric VADs has achieved new milestones and continues to quickly evolve; a majority 
of these more compact, pediatric VADs, however, have been designed to support the 
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systemic circulation in a normal biventricular physiology, not to support a cavopulmonary 
circulation [21, 36, 48]. All of these mechanical blood pumps were designed and 
developed for adult or pediatric patients with congestive heart failure (CHF) and to support 
the systemic circulation, not the unique anatomic physiology of the cavopulmonary 
connection [26]. These devices produce pressures that exceed the desired range to be used 
for cavopulmonary support.  Researchers theorize that a pressure boost of only 2 to 5 
mmHg may be sufficient to unload the cavopulmonary circulation in adolescent and adult 
patients who have a failing single ventricle [49]. The rising need for alternative therapeutic 
options for Fontan patients created the motivation for the development of an intravascular 
cavopulmonary assist device. 
 
1.3.3 Cavopulmonary Assist Devices  
 
Several institutions have begun to pursue research and development of 
cavopulmonary assist devices. Rodefeld and colleagues [22] have successfully 
demonstrated the use of the axial flow Hemopump to assist cavopulmonary flow in 
animals. This research group is also developing an innovative percutaneously-implantable, 
expandable propeller blood pump as a cavopulmonary assist device [22]. Limitations of 
this design include a wide distance between the rotor and blade-tip, increasing shear 
stresses, and an extremely short contact time with the thin propeller blades, preventing 
flow control downstream. Riemer et al. [50] at the Stanford University have used a sheep 
model of the total cavopulmonary connection to test the response to the Thoratec 
HeartMate II axial flow blood pump (Thoratec Corporation, Pleasanton, CA). These 
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studies demonstrated a baseline return of cardiac output, inferior vena caval flow, and 
arterial pressures. Similarly, the research team at the University of Colorado has made 
steady progress through numerical and in vitro studies on the development of an axial flow 
pump for proposed use in the IVC only [26].  
The Division of Cardiac Surgery and Department of Pediatrics at the University of 
Maryland Medical Center in Baltimore, MD recently published a case study on the use of 
the  Berlin Heart for the failing Fontan, providing more evidence for the continued 
research and development of a VAD for single ventricle physiologies [51]. An 18-month 
old patient was placed on cardiac support for 179 days, at which time the VAD was 
removed to optimize her general status. The patient expired 55 days post-VAD removal; a 
dislodged tracheostomy tube was claimed the probable cause of death.  
Another recent case study was performed by the Department of Cardiopulmonary 
Transplantation at the Texas Heart Institute at St. Luke’s Episcopal Hospital involving a 
14-year old male Fontan patient implanted with a left ventricular assist device as BBT. The 
HeartMate implantable pneumatic left ventricular assist system (IP LVAS) was implanted 
after the patient was placed on cardiopulmonary bypass during the operative procedure. 
The HeartMate IP LVAS proved full circulatory support for 45 days at which point a donor 
heart was available and implanted. The cardiac transplantation was a success, and the 
patient has remained health for more than 2 years post-transplant [52]. 
As proven by these research and clinical teams, the standard axial flow pump 
design has suitable characteristics for cavopulmonary assist. The aforementioned blood 
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pump designs, however, may be obstructive to flow in the event of rotational failure, and 
implantation requires invasive surgery.  
 
1.4 Noninvasive Counterpulsation and Minimally-Invasive Intravascular Assist 
 
In further support of this effort to develop alternative therapeutic options for Fontan 
patients, we are developing two modalities as a bridge-to-transplant, bridge-to-
hemodynamic stability, bridge-to-surgical reconstruction or long-term support alternative 
for these patients. The first modality is an external counterpulsation system as a long-term 
clinical management strategy. This technology involves using commercially-available, 
medical anti-shock trousers on single ventricle patients. The inflation and deflation of these 
trousers applies circumferential pressure to the lower extremities which translates into an 
increase in venous return pressure and cardiac output. We speculate that this 
counterpulsation system will improve functional and exercise capacity in these patients. 
  The second modality is a collapsible, percutaneously-placed, axial flow blood 
pump to support the cavopulmonary circulation. Mechanical pressure augmentation of 
blood flow in the cavopulmonary circulation would decrease elevated systemic venous 
pressure and increase ventricular preload. This type of blood pump, which is specifically 
designed to support the unique anatomic and physiologic conditions of the univentricular 
circulation, has never been developed.  
The intravascular, axial flow blood pump with a magnetically levitated rotor and a 
uniquely shaped protective cage. Figure 5 illustrates the conceptual design of the blood 
pump. The intravascular axial flow pump is designed for percutaneous positioning in the 
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inferior vena cava (IVC). The outer protective cage has radially arranged filaments that 
serve as touchdown surfaces to protect the vessel wall from the rotating components. Each 
filament is hydrodynamically designed to reduce drag and to maximize energy production 
from the rotating, engineered impeller blades. Currently the rotating pump consists of an 
impeller with four uniquely designed and helically wrapped blades to maximize energy 
transfer. Pump rotation is induced through a motor-magnetic bearing suspension, which 
levitate and rotate the impeller within the protective cage of filaments. An outlet nose is 
also located at the outflow of the pump to physically limit the axial movement of the 
impeller, to connect the cage filaments, and to house bearings which support the impeller 
during operation. The blade tip-to-tip diameter of the first generation design is 14 mm in 
the fully open configuration. In this study, for the purposes of measuring hydraulic 
performance, the pump prototype was mounted to a drive-shaft that was supported by 
mechanical bearings. The target design for the intravascular pump is to generate flow rates 
of 0.5 to 4 L/min with pressure rises of 2 to 25 mmHg for rotational speeds of 3000 to 6000 
RPM.  
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Figure 5: Conceptual Design of the Axial Flow Blood Pump.  (A) The device consists 
of a protective sheath with cage filaments, a rotating shaft and catheter, an impeller blades, 
diffuser region, and inlet and outlet sections. (B) Position of the cavopulmonary assist 
device in the IVC of the TCPC for Fontan patients. It is designed to augment pressure and 
thus flow in IVC and subsequently drive blood into the left and right pulmonary arteries 
(LPA and RPA) while supporting the incoming flow from the superior vena cava (SVC). 
 
 
1.5 Project Goal and Objectives 
 
 The goals of research for this M.S. thesis included the design, development, and 
evaluation of two modalities augment Fontan circulatory hemodynamics and cardiac 
function. A dual methodical approach to improving Fontan function was determined by the 
need for both preventative hemodynamic assistance and mechanical assistance to provide a 
bridge-to-transplant, bridge-to-surgical reconstruction, or bridge-to-recovery. The 
following are the objectives of this research:  
1. Obtain a thorough understanding of the unique anatomy and physiology of the Fontan 
surgical intervention and circulatory impact 
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2. Determine the parameters and engineering design specifications for circulatory 
augmentation of Fontan hemodynamics. 
3. Design and retrofit adult and pediatric size external pressure garment for a noninvasive, 
preventative approach for hemodynamic support for Fontan patients. 
4. Contrive and compose pressure garment protocols and obtain IRB approval for MAST 
clinical trials.  
5. Conduct MAST clinical trials on two patients during cardiac catheterizations at the 
Medical College of Virginia. 
6. Design and conduct numerical analyses on an intravascular, axial flow blood pump for 
minimally invasive mechanical circulatory support for Failing Fontan physiology 
to serve as a bridge-to-transplant, bridge-to-surgical intervention, or bridge-to-
recovery.  
7. Generate computational models for the total cavopulmonary connection (TCPC) 
Fontan including idealized configurations and patient specific configurations 
derived from MRI images.  
8. Conduct computational fluid dynamics (CFD) analyses on TCPC models with 
intravascular blood pump mechanical support.  
9. Perform the following analyses: pressure-flow, blood damage, shear stress, quasi-
steady state, and energy loss calculations.  
This thesis project provided insights into two forms of therapeutic treatments for Fontan 
patients. Achievement of these objectives resulted in substantial progress in the 
development of both modalities to address a significant human health problem.  
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1.6 Thesis Outline 
 
  This thesis reports two methods of circulatory augmentation for Fontan patients. 
The design and development of two mechanical modalities is detailed in subsequent 
chapters. Chapter 2 reports the construction of a noninvasive mechanical circulatory 
augmentation garment designed improve hemodynamics by reducing the workload of the 
systemic ventricle and providing increased pressure and blood flow to the lungs. The goal 
of the external circulatory augmentation garment is to provide patients with a therapeutic 
medical device for use at home to alleviate some cardiac workload thus providing a 
preventative approach to combat the ensuing Failing Fontan physiology.   
Chapter 3 reports the design and development of an intravascular, axial flow blood 
pump intended as a minimally invasive approach for mechanical circulatory augmentation 
of the Failing Fontan physiology. Computational fluid dynamic (CFD) analyses were 
performed with the pump placed in idealized and patient specific TCPC models. The 
results from both the counterpulsation studies and numerical simulations are reported in 
Chapter 4. Chapter 5 discusses the success and usefulness of both devices and indications 
for clinical use. Conclusions and future research expectations and goals are detailed in 
Chapter 6. 
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CHAPTER 2 METHODS AND MATERIALS: 
COUNTERPULSATION 
 
2.1 Theory of External Circulatory Augmentation 
Traditionally mechanical cardiovascular assist devices are invasive and designed 
specifically for adult patients suffering from congestive heart failure. The success of these 
devices in adults with CHF is well reported and discussed in earlier sections. Though these 
traditional mechanical circulatory support devices have been shown to mediate the failing 
Fontan physiology prior to full transplant, current research indicates device success as only 
a short term bridge to transplant, not for use over an extensive period of time [21, 23, 27, 
48]. Additionally, these devices require an invasive procedure for implementation and no 
clinically available device to date has been designed to specifically augment the unique 
circulatory demands of a Fontan.  
The theory of external circulatory augmentation can be contrived from studying 
skeletal musculature during exercise. The extension and contraction of skeletal muscle 
during exercise is shown to augment blood flow through a pumping action generated by 
the propulsion of blood forward upon muscular contraction. By applying external pressure 
to the extremities it is possible to mimic this pumping action.  
In an attempt to achieve the goals of mechanical circulatory assistance while 
reducing the surgical risk and cost to patients, we venture to apply external pressure to the 
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lower limbs as a preventative measure and long-term clinical treatment for Fontan patients. 
In the future we plan to employ external pressure to the lower limbs from a novel medical 
device designed to augment venous return for patient use at home. This device will assist 
patients through the augmentation of systemic blood flow to the pulmonary arteries, thus 
reducing ventricular workload, increasing venous return and pulmonary perfusion, and 
reducing cardiac afterload. Our review of literature and preliminary studies provide a 
proof-of-concept [53-56]. Two available technologies fit the criteria for obtaining relevant 
data for our intended contrivance: clinical application of Medical Anti-Shock Trousers 
(MAS trousers) and enhanced external counterpulsation (EECP). 
 
2.2 Historical Predecessors 
2.2.1 Military/Medical Anti-Shock Trousers 
The origin of MAS trousers dates back to 1903, when the developer, George Crile, 
discovered the concept of counterpressure for treatment of hypotension associated with 
surgical procedures [57]. Crile developed and constructed the first counterpressure medical 
device as a pneumatic double layered rubber suit designed exerted uniform pressure upon 
inflation. Since Crile’s time, MAS trousers have been updated and are part of protocol for 
every ambulance to use in situations of urgent assistance to patients suffering hypovolemic 
shock [58].  MAS trousers apply a fixed external pressure through pneumatic means to 
maintain a systolic pressure of 100 mmHg through increasing impedance of blood flow to 
the lower extremeties.  
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2.2.2 Enhanced External Counterpulsation 
      In contrast to MAS trousers, enhanced external counterpulsation (EECP) is a non-
invasive counterpulsation technique designed as a therapeutic alternative for adult patients 
suffering from ischemic heart diseases. Approved by the Food and Drug Administration 
(FDA) in 1995, EECP has been demonstrated as safe and effective in the treatment of 
angina.  A Multicenter Study conducted by Werner et al. of more than 5000 patients from 
over 100 centers concluded that EECP decreases angina episodes and extends the time to 
an exercise-induced angina episode [56]. 
 EECP is an electrocardiogram-triggered inflation and deflation of pressure cuffs 
wrapped around a patient’s lower extremities. The cuffs are inflated and deflated 
sequentially and circumferentially, resulting in the propulsion of retrograde blood flow 
through the arteries thus increasing coronary perfusion during diastole (ventricular filling).  
Figure 6 illustrates the inflation-deflation pattern timed with the cardiac cycle.  
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Figure 6: Electrocardiogram-trigged EECP.  External pressure applied to the lower 
limbs is triggered by the cardiac cycle. Diastolic inflation promotes retrograde flow to the 
coronary arteries[59]. 
 
In 2002, Ma et al. [53] performed a clinical trial on 10 pediatric patients to assess the 
usefulness of using external counterpulsation early postoperatively after the Fontan 
conversion at the Childern’s Medical Center in Dallas, TX. The study focused on the 
benefits of counterpulsation when applied to patients immediately postoperative for 10 
minutes. Though the authors state success with safe application to pediatric patients and an 
increased in cardiac index, no further trials were published.  
 
2.2.3 Application of Pulsation Technology to Fontan Patients 
Due to the extensive demonstration of success in adult CHF patients, it is expected that 
EECP or a similar technology (i.e. retrofitted MAS trouser configuration) would have 
superior results on pediatric CHD patients. This assumption is based on the symptomatic 
and physiological similarities between these two categorical patients. Their pathological 
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conditions arise from the common source of poor myocardial functionality. 
Counterpulsation therapy delivered with cardiac synchronization has consistently 
demonstrated immediate improvement in exercise tolerance, myocardial perfusion, venous 
return, and cardiac output, with several long-term benefits such as improved endothelial 
function, increased peripheral oxygen uptake, and augmented ventricular systolic and 
diastolic function [54, 56]. By focusing on the benefits derived from pulsation in 
conjunction with simplification of the device, it is possible to develop a noninvasive, 
external pulsation device for at home therapeutic use without the need for outpatient 
expenditures. 
Therefore, we executed a clinical study using commercially available MAS trousers on 
Fontan patients. We hypothesized that routinely administered, non-invasive, external 
counterpulsation will: 1) enhance flow from the great veins through the lungs, and 2) will 
improve functional and exercise capacity in these patients with single ventricle physiology. 
We propose to initially evaluate this hypothesis by performing a feasibility study on 
pediatric patients and young adults (ages of 10 to 45) with congenital heart disease. This 
study measured the increase in venous pressures and cardiac output with circumferentially 
applied, external pressures on the lower extremities using commercially available medical 
anti-shock trousers. Figure 7 below illustrates the location of external pressure application 
via MAS trousers.  
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Figure 7: External pressure application to lower limbs and abdomen using MAS 
trousers. Hypothesized forward propulsion of blood, illustrated as a bolus in the mid-thigh 
above, due to external pressure to augment Fontan circulatory hemodynamic.  
 
 
2.3 New Pulsation Device      
Two sets of MAS trousers (David Clark Company Incorporated, Worcester, MA, U.S. 
Patent No. 3933150) were procured and retrofitted for the counterpulsation studies: an 
adult size and a pediatric size. The adult and pediatric size differed in length of lower 
extremity cuffs, width of the abdominal cuff, and circumferential length of the abdominal 
cuff. The pressure compartments on these MAS trousers were individual such that the 
abdominal sections were interchangeable as well as the lower extremity sections. This 
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provided allowance for some degree of personalized fit for the patients involved in the 
study. For example a tall slender subject could use the adult size lower extremity sections 
in conjunction with the pediatric size abdominal section.  
System pressure application was provided via two means of airflow, coarse and fine 
adjustments, laid in series to the pressure garment. Bulk airflow to generate pressures 
accurate within approximately 10 mmHg originated from a standard air pump (Intertek 
Listed, Model: HB-505B). The air pump provided the coarse pressure adjustment to 
quickly elevate the pant pressure application to the patient to the desired level. A hand 
pump found on most sphygmomanometers was utilized for fine adjustments, elevating and 
relieving pressures within approximately 1 mmHg accuracy. In conjunction, the coarse and 
fine pressure applicators were capable of providing the external pressure application for the 
clinical trials.  
The pressure gage was added to the system in parallel to airflow through the trousers 
compartments, downstream of the pump and upstream of the patient. A standard dial 
pressure gage found on most sphygmomanometers was used to detect and approximate 
trouser pressure. Figure 8 below demonstrates the design and layout of the retrofitted 
MAS-trousers.  
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Figure 8:  Schematic of retrofitted MAS trousers used for counterpulsation clinical 
trials.   
 
 
2.4 Clinical Study 
VCU Investigational Review Board (IRB) approval was obtained for this study (HM 
#11906). The study population consisted of volunteer subjects aged 10 to 45 years who are 
recruited by staff and participating personnel. All subjects had a previously scheduled, 
dual-sided, cardiac catheterization. To-date, two subjects have been recruited.  
The subjects were examined prior to enrollment. The exclusion criteria are as follows: 
recent surgery or Fontan conversion within one year or less, cognitive impairment, 
uncontrolled arrhythmias, history of pulmonary embolism or deep vein thrombosis, 
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Exclusion Criteria 
1. Uncontrolled Arrhythmias 
2. Nonsustained ventricular tachycardia (NSVT) 
3. Recent Pulmonary Edema 
4. Recent prognosis of Deep Vein Thrombosis 
5. Uncontrolled Hypertension 
6. Abdominal Aortic Aneurysm  > 4.0 cm 
7. Uncontrolled Congenital Heart Failure 
8. Acute Myocardial Infarction 
9. Aortic Insufficiency 
10. Mitral or Aortic Stenosis 
11. Excessive Tachycardia 
12. Marked Bradycardia 
13. Bleeding Diathesis 
14. Symptomatic peripheral vascular disease 
15. Unsuitable deformity in lower extremity anatomy 
 
uncontrolled hypertension, uncontrolled congestive heart failure, clinically significant 
valvular disease (e.g. aortic regurgitation), acute myocardial infarction, excessive 
tachycardia or marked bradycardia, bleeding diathesis, absent pedal pulses, lower 
extremity and pulmonary edema, aortic aneurysm, and diaphragmatic hernia [54]. Table 1 
summarizes these exclusion criteria. Neither of the participating subjects met any of these 
criteria. 
Table 1: Exclusion Criteria for clinical trial. 
 
 
 
 
 
 
 
After obtaining informed consent, the patient was prepped for the previously scheduled 
cardiac catheterization. The subjects were placed in the supine position with the MAST 
garment applied but not inflated. A blood pressure cuff was wrapped around the patient’s 
arm for routine measurements; a pulse oximeter was placed on the patient’s index finger to 
measure oxygen saturation and heart rate during the study. Standard electrocardiogram 
leads were also appropriately located. A catheter was then inserted into the femoral vein 
and/or artery after the site had been cleansed and numbed with a local anesthetic, and 
according to the VCU standard protocol for cardiac catheterization. 
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Baseline measurements of blood pressure, cardiac output, respirations, right atrial 
pressure / central venous pressure, and pulmonary capillary wedge pressure, O2 sat, and 
heart rate were taken. Based on the patient’s diastolic pressure, we determined three 
separate pressure intervals to evaluate, up to 20 mmHg above their diastolic pressure.  
 After a first set of vital signs were obtained, the first pressure level was administered. 
The MAS trousers were inflated and a circumferential pressure was applied to the lower 
extremities similar to a blood pressure cuff. This pressure was held for 20 to 40 seconds 
and then released for 10 seconds. The pressure was applied again. These intermittently 
applied pressures at the first interval occurred for 3 to 5 minutes. Clinical measurements 
were ongoing. 
At the conclusion of this 3 to 5 minute first test period, the patient’s vital signs 
were reassessed and the MAS trousers were deflated. The patient rested for 3-5 minutes. 
Then, the second pressure level was tested, which is slightly higher than the first interval. 
The MAS trousers were inflated and a circumferential pressure was applied to the lower 
extremities. This second interval pressure was held for 20 to 40 seconds and then released 
for 10 seconds. The pressure was then applied again. These intermittently applied 
pressures at the second interval occurred for 3 to 5 minutes. Clinical measurements were 
ongoing. 
 At the conclusion of this 3 to 5 minute second test period, the patient’s vital signs were 
again reassessed and the MAS trousers were deflated. The patient rested for 3-5 minutes.  
Finally, the third and last pressure level was evaluated. This third interval pressure was 
held for 20 to 40 seconds and then released for 10 seconds. The pressure was then applied 
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again. These intermittently applied pressures at the third interval occurred for 3 to 5 
minutes. Clinical measurements of aortic systolic and diastolic pressures, pulmonary 
pressures, and TCPC pressure were ongoing. Upon completion, a final set of vital signs 
was reassessed and the MAS trousers were deflated. The patient was able to rest for 3 to 5 
minutes. After 5 minutes, a final set of baseline vitals was obtained. 
Deflation of the anti-shock trousers was carefully completed in order to maintain 
cardiac stabilization. We ensured that the subjects were not exhibiting any signs of shock 
and that they had a stable, strong, and regular heart rate, respirations, and blood pressure. 
Vital signs were carefully monitored during the deflation process. 
All measurements were recorded in manner that is in compliance with IRB rules 
and HIPPA regulations. The subsequent table is a sample spreadsheet as indicative of the 
data recorded for each study.  
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Table 2: Sample data spreadsheet for clinical trials.  
 
2.5 Chapter Summary 
 Counterpulsation has been shown to improve cardiovascular hemodynamics and 
provide symptomatic relief in adult patients suffering from CHF. Inferring from the 
similarities in symptoms between adult CHF patients and patients with failing Fontan 
physiology it was hypothesized that external pressure augmentation to the lower limbs of 
Fontan patients would provide them hemodynamic relief and reduce cardiac workload.  An 
 
Study Number:         Age/Sex    Diagnosis   
        
  Baseline Measurements 
Recording Time BP HR Resp. O2 sat. Left atrial / CVP Pulmon. Cap. Wedge 
1              
2               
3               
4               
5               
  Applied External Pressure of _________ 
 Time BP HR Resp. O2 sat. Left atrial / CVP Pulmon. Cap. Wedge 
1               
2               
3               
4               
5               
  Applied External Pressure of _________ 
  Time BP HR Resp. O2 sat. Left atrial / CVP Pulmon. Cap. Wedge 
1               
2               
3               
4               
5               
  Applied External Pressure of _________ 
  Time BP HR Resp. O2 sat. Left atrial / CVP Pulmon. Cap. Wedge 
1               
2               
3               
4               
5               
  Baseline Measurements 
Recording Time BP HR Resp. O2 sat. Left atrial / CVP Pulmon. Cap. Wedge 
1               
2               
3               
4               
5               
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IRB approved study was conducted over the course of Fall 2008 to Spring 2010. The 
clinical trial was conducted during prescheduled cardiac catheterizations and employed 
retro-fitted MAS trousers. Two patients were recruited and results from the clinical trials 
are provided in Chapter 4.   
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CHAPTER 3 METHODS AND MATERIALS: INTRAVASCULAR 
BLOOD PUMP 
 
In contrast to the completely non-invasive and external pulsation device, another 
approach to augment pressure in the total cavopulmonary connection (TCPC) of Fontan 
patients involves the use of an intravascular blood pump. This thesis evaluated the use of 
such a pump in the inferior vena cava (IVC) through numerical means. The cavopulmonary 
assist device represents a minimally-invasive technique to support Fontan patients in the 
cardiac catheterization lab. 
As discussed in previous chapters, repair of univentricular physiologies through the 
operative Fontan procedure manifests a new, “man-made” circulatory pattern for these 
patients deriving from a direct connection of the great veins to the pulmonary arteries. In 
recent years, progress in surgical advances of the TCPC has reached a plateau. Therefore, a 
rising interest in the implementation of an intravascular blood pump in the IVC has 
emerged.  
Normal cardiac anatomy utilizes the right ventricle as a pumping chamber to propel 
blood forward into pulmonary circulation. Due to their univentricular physiology, Fontan 
patients have passive blood flow to the lungs. The use of an axial flow blood pump in the 
IVC would compensate for the loss of energy from the univentricular physiology and serve 
to recoup and maintain hemodynamic stability for patients suffering from a failing Fontan. 
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3.1 Conceptual Pump Design 
 
 In order to produce a more effective and minimally invasive bridge-to-transplant, 
bridge-to-recovery, or bridge-to-surgical reconstruction, we have developed a collapsible, 
percutaneously inserted, magnetically levitated axial flow blood pump to support the total 
cavopulmonary connection (TCPC) of a failing Fontan in adolescent and adult patients. 
Our intravascular pump would provide mechanical augmentation of blood flow from the 
inferior vena cava to the lungs, thus enhancing cardiovascular hemodynamics through 
improved systemic pressure, increased ventricular filling, and augmented cardiac output. 
 The axial flow blood pump is designed with a catheter-mounted impeller, diffuser 
blades surrounding the pump hub tip, protective cage filaments and a motor for magnetic 
levitation and rotation. The impeller consisted of a hub and 3 counterclockwise oriented 
blades and the diffuser was designed with a hub and 4 clockwise oriented blades. Figure 9 
outlines the conceptual design of this pump. The development of this pump was completed 
through the use of pump design equations and computational fluid dynamics (CFD) 
analyses. One of the main objectives of this thesis was to numerically model the interactive 
fluid dynamics of the pump and the cavopulmonary circulation in an idealized TCPC 
geometry and a patient-specific TCPC geometry. 
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Figure 9: Intravascular Axial Flow Blood Pump for 
Cavopulmonary Assist. This intravascular cavopulmonary assist 
device consists of a protective sheath, cage filaments, a rotating 
shaft and catheter, impeller region and diffuser region. The axial 
flow blood pump was numerically modeled in a straight tube to 
assess hydraulic performance. Flow entered downstream of the 
pump at the inlet(8), traveled through the pump region, accelerated 
by the impeller blades(5) and exited at the outlet(9). 
 
 
3.2 Methods and Materials: Computational Fluid Dynamics 
 
3.2.1 CFD Theory 
  
 Computational fluid dynamics (CFD) has been utilized for decades to generate 
numerical models for blood flow though arteries, veins, stents, grafts, and blood pumps 
[60-63]. Numerical models serve a purpose in the design and development process by 
generating reliable predictors of pump performance and flow profiles. The CFD approach 
involves the division of a complex three-dimensional fluid domain into a congregation of 
smaller, discrete volumetric regions or mesh elements [64]. Mesh elements are linked at 
common nodes and through these connections the equations of motion can be algebraically 
solved. By characterization and analysis of fluid flow through each discrete node, the fluid 
dynamics of the entire fluid domain can be captured. Figure 10 illustrates the 
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computational model of the impeller region only, along with the computational element 
with nodal locations. 
 
Figure 10: Computational Model of Axial Flow Impeller: A. Meshed model having four regions 
– inlet pipe, spindle, impeller with 4 blades, and outlet. B. Numerical analysis involves dividing the 
complex three-dimensional fluid model into smaller volumetric regions or mesh elements with 
nodes to mathematically characterize the fluid dynamics of the pump. 
 
 
3.2.2 Software Programs 
 
 Several software programs were employed for the CFD work conducted during the 
course of this thesis: MIMICS (Materialise, Leuven, Belgium), SolidWorks (SolidWorks 
Corporation, Concord, MA), ANSYS (ANSYS Incorporated, Canonsburg, PA), Bladegen 
(ANSYS Incorporated, Cansonsburg, PA) and MatLab (The MathWorks Incorporated, 
Natick, MA).  In order to assess the interactive dynamics between the pump and the TCPC 
physiology, two numerical models were created: 1) an idealized TCPC geometry based on 
a Ryu et al. [65], and 2) three-dimensional patient-specific models that were constructed 
from magnetic resonance imaging (MRI) data of single ventricle patients. MIMICS 
software was employed to transform two-dimensional MRI images into a three-
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dimensional point cloud mesh. After numerous smoothing iterations, the three-dimensional 
point cloud mesh was imported into SolidWorks to generate a solid body model. 
SolidWorks was also utilized for the design and construction of an idealized TCPC model 
described by Ryu et al. [65] and elements of the intravascular pump including pump hub 
and protective cage. The pump impeller and diffuser blade geometries were generated 
using Bladegen.  ANSYS-CFX, a 2nd order accurate fluid solver, was employed to simulate 
flow through all of the computational models. This CFD program solves the equations for 
the conservation of mass and momentum in terms of the dependent variables, velocity and 
pressure, according to the Reynolds-Averaged Navier Stokes (RANS) method. The 
software Matlab was used to conduct a blood damage study for various pump operating 
conditions.  
 
3.2.3 Simulation Models 
 
 In order to assess the interactive dynamics between the axial flow blood pump and 
physiology numerical simulations were completed in two Fontan models: an idealized 
TCPC model generated in SolidWorks and a patient specific TCPC model generated in 
MIMICS and SolidWorks.  
 
3.2.3.1 Idealized TCPC 
 
 A numerical model of the idealized cavopulmonary connection was constructed 
with the intravascular pump integrated in the inferior vena cava (IVC). This work builds 
upon the idealized TCPC geometry as described by Ryu et al. [65] and previous studies 
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with the intravascular blood pump. The following three models were analyzed: 1) an 
idealized TCPC with a 1-diameter offset without a blood pump, 2) an idealized TCPC with 
a 1-diameter offset and an axial flow blood pump having only a 3-bladed impeller, and 3) 
an idealized TCPC with 1-diameter offset with an axial flow blood pump having a 3-
bladed impeller and 4-bladed diffuser. Pump placement for models 2 and 3 were in the 
IVC. Figure 11 illustrates the three idealized TCPC models. 
 
 
 
Figure 11: Idealized TCPC Models. Three idealized TCPC models were generated from 
geometry described by Ryu et al. IVC, SVC, LPA, and RPA vessel diameters were set to 
13.4 mm. A) Idealized TCPC with no pump. B) Position of the intravascular blood pump 
with impeller and diffuser placed in the IVC. Since the position of the intravascular blood 
pump with only the impeller is so similar to B), it has not been included. The intravascular 
blood pump is placed in the IVC for adult patients with failing single ventricle physiology. 
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3.2.3.2 Anatomical TCPC 
 
 Provided that actual Fontan patient anatomy retains vascular contours and angles 
incapable of being captured in an idealized model, patient specific computational models 
were constructed from MRI’s obtained from four Fontan patients. Patient number and 
cardiovascular anatomy are provided in Table 3.  
 
Table 3: MRI Fontan Patient 
Information. Four three-dimensional 
patient specific Fontan models were 
generated from patient MRI images. 
 
 
Eight three-dimensional models were constructed. Models 1 through 3 
demonstrated the extra-cardiac TCPC Fontan anatomy from patients 1-3 respectively. 
Models 4 through 6 demonstrated TCPC anatomies from patients 1-3 with an axial flow 
pump having a set of impeller and diffuser blades. Model 7 demonstrated a Glenn anatomy 
from patient 4, and Model 8 demonstrated a Glenn anatomy from patient 4 with an axial 
flow pump having a set of impeller and diffuser blades. Pump placement for models 1-3 
were in the IVC and for model 4 was in the SVC. Figure 12 illustrates the four patient 
specific TCPC models. Generation of the patient specific three-dimensional solid bodies is 
elucidated in Figure 13 for patient 1 corresponding to model 1 and model 5.  
Patient Number Anatomy 
1 Extra-Cardiac Fontan 
2 Extra-Cardiac Fontan 
3 Extra-Cardiac Fontan 
4 Glenn 
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Figure 12: Patient specific anatomical TCPC models. Models 1-4 correspond to patients 
1-4 respectively. Models 5-8 correspond to models 1-4 with the axial flow blood pump 
place in the IVC for models 5-7 and SVC in model 8. 
 
Figure 13: Generation of a patient specific computational model. A) Point cloud B) 3-
D suface mesh C) Solid body anatomical model with vascular extensions D) Patient 
specific model with pump placement in the IVC.   
 
 
 
 
40 
3.2.4 Simulation Setup 
 
For this thesis project, the interactive fluid dynamics of the pump and the 
cavopulmonary circulation were analyzed numerically an idealized TCPC geometry and 
one patient-specific TCPC geometry with the axial blood pump integrated into the IVC. 
 
3.2.4.1 Grid Generation 
 
 We employed CFD software from ANSYS Inc. to simulate flow through all 
computational models. CFX-Mesh, an ANSYS mesh generation, software was used to build 
tetrahedral element-based meshes for the CFD analyses. Grid generation was performed by 
other personnel in the research laboratory. Previous grid convergence studies provided 
insight as to appropriate regional grid densities for the computational models [25]. Grid 
density and convergence studies were completed for grid quality assurance. This process 
included incremental adjustments to grid size until the performance results deviated less 
than 2%. For each simulation, the incremental time step, or relaxation factor in a steady 
state study, was specified as 0.001 to 0.005 with a maximum criterion of normalized 
convergence residual at 1x10-3 [61, 66].  
 
3.2.4.2 Configuration and Boundary Conditions 
 
Blood flow through the pump, cage, and total cavopulmonary connections was 
defined to be steady with constant boundary conditions and velocities for these 
simulations.  The no-slip boundary condition was assigned to the stationary walls such that 
the fluid velocity values along the boundary would equal zero.  A stationary wall boundary 
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was applied to the internal housing regions of the pump.  The impeller blades and hub were 
specified as rotating walls in the counterclockwise direction in accordance with the blade 
orientation.  The protective cage filaments were modeled as stationary walls, and the 
diffuser blades and hub were modeled to be spinning at the same speed as the impeller. 
The frozen rotor interface linked regions of differing reference frames between the 
impeller domain and protective cage [67].  A uniform mass inflow rate and rotational 
speed were specified for each simulation. The outlet boundary surface was specified as an 
opening to capture any possible irregular flow conditions at the outflow. The outlet 
boundary conditions, such the left and right pulmonary arteries, were defined to have static 
pressures of 10, 14, 18, 22 and 26 mmHg. All of the vessel walls for the IVC, SVC, and 
pulmonary arteries are modeled as rigid tubes for this initial interactive assessment. 
 
3.2.4.3 Turbulence Model 
 
After successful mesh generation and boundary condition specification, the 
computational flow model was then implemented in the 2nd order accurate fluid solver, 
ANSYS-CFX.  This program solves the equations for the conservation of mass and 
momentum in terms of the dependent variables, velocity and pressure, according to the 
Reynolds-Averaged Navier Stokes (RANS) method.  The RANS method is used to 
simulate the entire flow field with acceptable averaged quantities for the mean flow and 
fluctuating flow values. Details of the conservation of mass, Navier-Stokes equation of 
motion, and Reynold-Averaging procedure are outlined below.  
Law of Conservation of Mass 
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 The differential form of the continuity equation or conservation of mass is derived 
by the Eulerian method of analyzing the mass flow into and out of a control volume of 
infinitesimal size. As defined using Einstein summation convention the law of 
conservation of mass is [68, 69]: 
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where t represents time, ρ is the fluid density, and Ui is the 
three-dimensional velocity vector components of flow summed 
over the index i. 
 
 
Navier-Stokes Equation of Motions 
 
 By applying Newton’s law of motion to an infinitesimal fluid element, the 
differential form of the law of conservation of momentum is defined in Einstein 
summation convention as follows: 
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where P signifies pressure, τij  is the stress tensor, xi 
represent spatial variables, and fi is the body force vector.  
 
 
Neglecting the body force due to gravity, the stress tensor for a Newtonian fluid is: 
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 where µv is the dynamic viscosity, µb = is the bulk viscosity (=2µv, 
/3), and δij is the Kronecker delta, a symmetric identity matrix 
(when i=j, then δij =1, and δij =0 for i≠j). 
 
 
Reynolds-Averaging Procedure 
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The value of scalar variables fluctuate in turbulent flow conditions therefore the 
instantaneous value of a scalar quantity is calculated as the sum of mean and fluctuating 
components. Using Reynolds-Averaging, ANSYS-CFX expresses the instantaneous scalar 
quantities in terms of mean values, neglecting the fluctuating component [68].  For any 
arbitrary quantity θ the instantaneous scalar value is: 
'
__
φθθ +=               [4] 
where θ  is instantaneous scalar value, θ  is the scalar’s mean 
component, and φ' represents the scalar’s fluctuating component. 
 
θ , the time-average of scalar’s mean component and φ', the time-average of fluctuating 
components are defined as below: 
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As observed in equation 6 the mean of individual fluctuating components is zero, but the 
product of fluctuating components is non-zero. For incompressible flows, the 
conservation of mean momentum is derived as below in Reynolds-Averaging form: 
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Averaging the left side of the equations using the nonlinear convection term results in the 
Reynolds stress tensor '' jiuuρ . Eddy viscosity approximations are used to relate Reynolds 
stress and turbulent fluctuating terms to mean flow variables resulting in the following 
equation: 
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where µt is the turbulent viscosity and k is the turbulent kinetic energy term. 
 
The Reynolds-Averaged viscous stress tensor below is defined for incompressible, 
Newtonian fluids: 










∂
∂
+
∂
∂
−=
i
j
j
i
vij x
U
x
U
_________
____
µτ                  [9] 
 
 
 The major drawback to Reynolds-averaging is the occurrence of higher order correlations 
between the mean and turbulent flow equations thus requiring a ‘closure scheme’ for these 
correlations or unknown turbulent stresses. Reynolds stress scheme, turbulent diffusion 
model, and two equation models are examples of the numerous closure models utilized for 
the RANS approach to model turbulent flow. Turbulence models in CFD codes solve the 
nonlinear Reynolds stress tensor in the Navier-Stokes equation by approximating turbulent 
flow conditions for the viscous dissipation and kinetic energy transfer. Turbulent viscosity, 
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µt, and turbulence kinetic energy, k, are be estimated by electing a turbulence model 
suitable for the defined conditions of the numerical simulations. 
 ANSYS-CFX has a number of different turbulence models, such as the k-ε 
turbulence model. The k-ε turbulence model solves the equations for k, the turbulent 
kinetic energy, and ε, the dissipation rate of k.  The dissipation rate of k or ε is also defined 
as the amount of k per mass and time converted to internal fluid energy by viscous motion.  
Several research groups have used the k-ε turbulence model for CFD simulations to design 
their artificial heart pumps [60, 62, 63].  Along with the k-ε model, we selected a scalable 
wall function to characterize and resolve wall flow conditions. 
 
3.2.4.4 Blood Properties 
 
 Constant viscosity values were defined for each simulation. The pump model and 
patient specific models were held at a constant viscosity value of 0.0035 kg/m*s 
corresponding to a hematocrit of approximately 33%, which reasonably represents 
pediatric patients suffering from congenital heart disease [70].  Hematocrit influence 
studies were conducted on the idealized TCPC model for three blood viscosities: 0.0035 
kg/m*s, 0.005 kg/m*s and 0.0065 kg/m*s corresponding to a hematocrit of 33%, 45% and 
55% respectively [62, 71]. A constant fluid density of 1050 kg/m3 was also applied to all 
simulations.  
The behavior of the blood in these simulations was assumed to be Newtonian [69]. 
At a constant viscosity Newtonian fluids demonstrate a linear relationship between shear 
stress and shear strain rate while non-Newtonian fluids exhibit a nonlinear relationship 
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between shear stress and shear strain rate. Though the heterogeneous composition of blood 
insinuates non-Newtonian behavior, Merrill et al. [72] experimentally found blood plasma 
to behave with Newtonian characteristics at a viscosity of approximately 1.2cP. Cokelet et 
al. [73, 74] experimentally determined that low hematocrit levels, approximately less than 
50%, blood plasma demonstrates a linear relationship between shear stress and shear strain 
rate, thus supporting Merrill et al. and confirming the assumption of Newtonian behavior 
as acceptable.  
 
3.2.5 Blood Damage Analysis 
 
A blood damage analysis was performed to consider the potential for hemolysis 
and thrombosis for this blood-contacting intravascular blood pump.  This blood damage 
model has been widely employed as a predictive tool in the development of several rotary 
blood pumps [71, 75, 76]. We used a blood damage technique that considers the three-
dimensional flow field and calculates a scalar stress (σ), which includes the six 
components of the stress tensor and represents the level of stress experienced by the blood 
[77]: 
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We utilized a maximum stress value of 425 Pa for 600 milliseconds as the design criterion 
in the development of axial flow VADs [25, 61, 62, 75]. We also examined fluid 
streamlines as indicative of numerically predicted fluid residence times within this 
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intravascular blood pump. Using a power law relationship between the scalar stress level 
and the exposure time, a blood damage index was estimated for the selected models [76], 
according to:  
 
βασ TCHbdHb ⋅⋅=/                 [11] 
 
where Hb is the hemoglobin content, dHb signifies the change in hemoglobin content due 
to blood trauma, σ corresponds to the scalar stress, T is the exposure time to the scalar 
stress levels, and C, α, and β reflect proportionality constants that are obtained by 
regressing experimental data.  The accumulation of stress and exposure time was summed 
along the streamlines. This approach provides a statistical estimate of damage to blood 
cells traveling through this blood pump, according to the following power law equation: 
∑ ∆⋅⋅= −
outlet
inlet
txD 765.0991.16108.1 σ                [12] 
where D represents the blood damage index and indicates a ‘probability’ of damage to red 
blood cells; t corresponds to the stress exposure time; and inlet and outlet symbolize the 
entrance and exit faces in the CFD model, respectively. This model only examined the 
relationship between scalar stress and exposure time to the level of stress for each particle; 
the analysis incorporated adiabatic and isothermal conditions.  To incorporate the stress 
history of the particles (cells), a Lagrangian tracking method was used.  The particle 
displacement was calculated using forward integration of the particle velocity over the time 
step (δt): 
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where x signifies the displacement and the superscripts o and n correspond to old and new 
values, respectively, as the analysis moves forward along the streamlines.  The numerical 
constants in Equation 3, relating the stress to the exposure time, were obtained by 
regression of experimental data in a Couette viscometer with an exposure time of 0.0034 to 
0.6 seconds for fluid stresses of 40 to 700 Pa [76, 78].  This range of investigation is 
comparable to the flow conditions and stress levels found in blood pumps [76, 78]. We 
seek a blood damage index below 2% for our target design [79]. Table 4 lists the details of 
this damage analysis, including the case number, number of particles released at the inlet 
port and operating conditions. 
 
Table 4: Blood Damage Operational Conditions. Blood damage analyses were 
performed on the idealized TCPC model.  
 
Normalized Index of Hemolysis: 
Koller and Hawrylenko [80] developed an equation that is routinely used to express 
blood damage in the experimental setting as a normalized index of hemolysis (N.I.H): 
Blood Damage Cases Flow Rate (LPM) Rotational Speed (RPM) Fluid Viscosity (cP) Number of Particles 
Case 1 3.5 5000 5 350 
Case 2 3.5 5000 3.5 350 
Case 3 3.5 4000 3.5 350 
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where fHb∆  is the measured increase in plasma free Hb concentration (g/L) during the test 
period, ∆t represents the duration of the test period (min), Ht denotes the hematocrit (%), V 
corresponds to the blood volume in the test circuit (L), and Q signifies the flow rate 
(L/min).  This equation is employed in designing heart pumps as well as other blood-
contacting medical devices [81, 82]. The in vitro N.I.H values can be related to the blood 
damage index according to the following equation [83].   
))(00015.0(.. DHIN =                       [15] 
We utilized this empirical relationship to estimate the normalized index of hemolysis in the 
computational models that were analyzed in this study and to compare these calculated 
N.I.H values to clinically used pumps. 
 
3.2.6 Energy Loss Calculations 
 
To assess the impact of the blood pump in the IVC on the total energy of the 
cavopulmonary flow conditions, we used the simplified control volume approach to 
calculate the energy losses through TCPC configuration with and without the pump [65]. 
As a common approach used when considering surgical optimization of the TCPC, this 
analysis allowed for the estimation of the energy loss or gain in the cavopulmonary 
configuration, according to the following equation: 
( ) ( )∑ ∑ ∑−=+−= outletouttotalinletintotaliiikkstaticloss QPQPAnuuuPE __)5.0( ρ     [16] 
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where  iistatictotal uuPP ρ5.0+=       [17] 
                                                                                                        [18]             
In the aforementioned equations, ρ corresponds to the fluid density, Pstatic is the static fluid 
pressure, ui symbolizes the components of the velocity vector, ni is the components of the 
outward surface normal vector of the control surfaces, Eloss represents the rate of energy 
consumption within the control volume, Ptotal is the total pressure including the static 
pressure component in addition to the kinetic energy component, and Qi is the flow rate at 
an inlet or outlet. A model of the TCPC alone with no pump in the IVC was created to 
directly compare the energy calculations to the model of the TCPC with a blood pump 
(impeller and diffuser) in the IVC. 
 
3.2.7 Simulation Execution 
 
 Steady state simulations were completed on the idealized TCPC model and patient 
specific TCPC model with and without the axial flow blood pump inserted into the IVC.   
 
3.2.7.1 Steady State Simulations 
 Over 900 numerical simulations were performed as part of this thesis project. Three 
main categories of operating conditions were investigated for both the idealized and patient 
specific TCPC models: blood flow rate, pulmonary arterial pressure, and pump rotational 
speed.  
 Blood flow rate considerations are critical to the development of any cardiovascular 
assist device.  The average resting cardiac output (CO) for pediatric and adult patients 
ranges from 1 to 8 liters per minute (LPM) [12, 61, 65]. Venous return (VR), or the flow of 
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deoxygenated blood from the body back to the heart, emerges to the cardiac musculature 
via two great caval veins: the superior vena cava (SVC) and the inferior vena cava (IVC). 
The superior vena cava returns deoxygenated blood from the head and upper body and the 
inferior vena cava returns deoxygenated blood from the torso and lower body. Under 
steady-state conditions VR equals CO where VR is the sum of SVC and IVC flows.  
Deriving from anatomical characteristics, VR is dominated by IVC flow for pediatric and 
adult patients and almost equally shared by IVC and SVC flows for newborns and infants.  
For infants IVC:SVC flow is approximately 50:50 and for pediatric and adults IVC:SVC 
flow is approximately 60:40 to 70:30 [12, 65]. The axial flow blood pump simulated for 
this thesis work is designed to augment venous return of pediatric and adult Fontan 
patients and consequently numerical simulations were conducted for flow rates of 1 to 8 
LPM distributed 60% IVC flow and 40% SVC flow.  
 Pulmonary arterial pressure considerations were also essential to accurate 
numerical modeling of the Failing Fontan physiology. On account of the Fontan single 
ventricle driving systemic blood flow, VR is transmitted directly to pulmonary circulation. 
Considering the cardiovascular system as a closed system, IVC and SVC flow must 
overcome pulmonary vascular resistance resulting in an increased after-load on the great 
veins whereas in normal biventricular circulation mean caval pressures are less than 10 
mmHg and mean arterial pressures are at least 15mmHg [12]. This thesis blood pump is 
designed to provide an after-load reducing agent to improve the Failing Fontan 
hemodynamics and therefore must be numerical simulated under elevated pulmonary 
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resistance conditions. Numerical simulations were conducted for the pressure range 10 
mmHg to 26 mmHg in the left pulmonary artery (LPA) and right pulmonary artery (RPA). 
 The third major operational condition investigated was the axial flow blood pump 
rotational speeds. Pump rotation is used to impart kinetic energy on blood flow and is 
influential to the pump’s ability to alleviate the poor hemodynamics of the Fontan 
physiology. Pump performance to augment venous return is a function of rotational speed 
and must be considered over a range of pressures and flow rates. Optimization of pump 
design with regard to implementation of diffuser blades and diffuser bladed orientation 
were also determined in part by rotational speed influence. Numerical simulations were 
conducted for rotational speeds of 1000 to 8000 RPM. 
 In order to determine the effect of blood viscosity on pump performance, steady 
state numerical simulations completed on the idealized TCPC model were performed with 
3 blood viscosities: 3.5cP, 5.0 cP, and 6.5 cP corresponding to hematocrits of 33%, 45%, 
and 55% respectively [70]. Parameters included all three major operational conditions as 
disclosed in the preceding paragraphs.   
 Fluid particle streamlines and scalar stress values were examined to predict the 
potential of hemolysis and thrombosis due to blood contact with the pump. 350 fluid 
particles were released at the IVC inlet of the idealized TCPC model for each of 3 blood 
damage cases aforementioned in Table 5. Of the 3 damage cases reviewed, 1 was at the 
pump design point (Case II) and 2 were off-design point (Case I, III). Off-design point 
damage indices were examined since the pump will often be operating off-design. Particle 
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residence time on the streamline and scalar stress exposure during contact with the pump 
and irregular flow patterns were used for the damage index calculations.   
 Energy gain calculations for both the idealized TCPC model and the patient 
specific TCPC model were completed by conducting simulations on the TCPC models 
without the axial flow blood pump. Parameters for the model simulations without pump 
included pulmonary arterial pressures of 14 mmHg, fluid viscosity of 3.5 cP, and flow 
rates of 1 to 4 LPM in the SVC and IVC. 
 
 
3.2.7.2 Quasi-Steady State Studies 
 
 A quasi-steady state study was performed on the idealized TCPC model with the 3-
bladed impeller and 4-bladed diffuser axial flow blood pump. The purpose of this study 
was to determine the optimal position for the diffuser blades to maximize pressure 
generation and to reduce flow vorticity at the outlet. The diffuser blades were 
incrementally rotated by 3° and a new grid was created for the diffuser blades at each 
rotational position. The new grid at each rotation increment was of the same size (within 
1%) and of the same grid quality as compared with the original diffuser model. The new 
meshes for the diffuser at each degree increment were then incorporated into the overall 
model and a new simulation was completed. Due to the four bladed geometry of the 
diffuser region, the achievement of a 90° incremental rotation captures the quasi-steady 
performance of the blades. Additional rotations above 90° would be unnecessary given the 
symmetry of the diffuser region. The boundary conditions in these simulations remained 
the same as for all other simulations conducted during this thesis. 30 different rotational 
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geometries and meshes were generated and evaluated for the diffuser region. The 
numerical simulations was conducted on the idealized TCPC model with a flow rate of 2 
LPM, pulmonary arterial pressures of 14 mmHg, pump rotational speed of 5000 RPM, and 
blood viscosity of 3.5 cP correlating to a hematocrit of 33%. 
 
3.2.7.3 Simulations Completed 
 Numerical simulations completed for pump performance in the idealized TCPC 
model and patient specific TCPC model are summarized in Table 5, 6 and 7 below. 
 
Table 5: Summary of steady state numerical simulations. 
Fontan Model Pump Rotational Speed LPA/RPA Pressure Flow Rate Blood Viscosity 
Idealized TCPC 1000 -8000 RPM 10 – 26 mmHg 1 – 8 LPM 3.5cP, 5cP, 6.5cP 
Patient Specific TCPC 1000 – 5000 RPM 14 – 22 mmHg 1 -5 LPM 3.5cP 
 
Table 6: Summary of quasi-steady state numerical simulations. Simulations were 
completed with the idealized TCPC model. 
Parameter Value 
Impeller Region 3 Blades 
Diffuser Region 4 Blades 
Rotational Increments 3o 
Flow Rate 2 LPM 
LPA/RPA Pressures 14 mmHg 
Pump Rotational Speed 5000 RPM 
Blood Viscosity 3.5 cP 
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Table 7: Summary of blood damage analyses numerical simulations. Simulations were 
completed with the idealized TCPC model at steady state.  
 
3.3 Chapter Summary 
 This chapter discussed the software employed to design and conduct numerical 
analyses on a minimally invasive approach for providing hemodynamic relief and a bridge-
to-recovery, -transplant, or -surgical reconstruction to patients with Fontan physiology. 
The axial flow blood pump was numerically simulated in an idealized TCPC model and 
patient specific TCPC model for performance evaluation under varying physiologic 
conditions and pump rotational speeds. Tablatures of all completed simulations were 
provided. The subsequent chapter provides results for both modalities investigated for this 
thesis work.   
Blood Damage Cases Flow Rate  Rotational Speed  Fluid Viscosity  Number of Particles 
Case 1 3.5 LPM 5000 RPM 5 cP 350 
Case 2 3.5 LPM 5000 RPM 3.5 cP 350 
Case 3 3.5 LPM 4000 RPM 3.5 cP 350 
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CHAPTER 4 RESULTS 
 
 
4.1 MAST Clinical Trial Results 
Results from this clinical trial with two patients (n=2) agree with literature in that 
MAS trousers successfully augmented venous return, systemic pressure, cardiac output, 
and blood pressure [55, 57, 84, 85]. Both patients demonstrated significant augmentation 
in pressure levels during external pressure application. Common trends with both patients 
included an increase in cardiac pressure during inflation holds and return to baseline during 
deflation holds. The cyclic inflation/deflation cycles are clearly visible for patient 1; 
patient 2 data reflected the cyclic inflation/deflation during the upper range of external 
pressure application. This discontinuity between patient cardiac reactions is discussed in 
full in the discussion section.  
4.1.1 Pressure Augmentation 
 The three external pressures were applied to the lower limbs of both patients and 
abdominal section of patient 1 were determined based upon mean baseline calculations. 
Mean baseline diastolic pressure for patient 1 was 47 mmHg; external pressure application 
consisted of cyclic inflation/deflation at 37 mmHg, 47 mmHg, and 57 mmHg with 
rudimentary rest periods between each level. Patient 2 had a mean baseline diastolic 
pressure of 79 mmHg and the external application was cycled at 69 mmHg, 79 mmHg, and 
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89 mmHg with similar rests periods between each level. Table 8 below outlines patients’ 
baseline measurements and applied external pressure levels.  
Table 8: Patient baseline and applied external application data. 
Patient Age Gender Cardiac Anatomy 
Baseline Aortic Pressures (mmHg) 1st Pressure 
Cycle 
(mmHg) 
2nd Pressure 
Cycle 
(mmHg) 
3rd Pressure 
Cycle 
(mmHg) 
Systolic 
BP Diastolic BP MAP 
1 37 female Extra-Cardiac Fontan 94 47 63 37 47 57 
2 24 male Intra-Atrial Fontan 117 79 92 69 79 89 
 
Patient 1 developed measurable pressure augmentations during all three external 
pressure levels; increase in cardiac pressure ranged from approximately 9-15 mmHg in 
systolic blood pressure, 4-10 mmHg in diastolic blood pressure, and 5-11 mmHg in 
calculated VMAP. Average hemodynamic improvements to patient 1as determined by 
pressure increase ranged from 10% during the first cycle at 37 mmHg external pressure to 
20% during the third cycle conducted at 57 mmHg external pressure. Figure 12 illustrates 
average pressure augmentation measured at the aortic arch as a function of external 
pressure application.  
 
Figure 14: Patient 1 
aortic augmentation to 
baseline pressures as a 
function of applied 
external pressure.  
58 
Patient 2 also developed detectable pressure rises during cycles of external pressure 
application demonstrating systolic pressure augmentation of approximately 10 -13 mmHg, 
diastolic increase of 5-7.5 mmHg and improvements to calculated VMAP of 3 – 9 mmHg. 
Patient 2 reported lower levels of hemodynamic improvement with dynamic 
inconsistencies and unexpected trends discussed further in Chapter 5. Figure 13 illustrates 
the average increase in blood pressure as a function of the external pressure application. 
Table 9 below outlines the average pressure augmentation for both patients as compared to 
the initial baseline measurements.  
 
 
 
 
 
 
 
 
 
Figure 15: Patient 2 aortic augmentation to baseline pressures as a function of 
applied external pressure.  
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Table 9: Average augmentation to systolic, diastolic, and calculated VMAP blood 
pressures of patient 1 and patient 2 as compared to baseline measurements. Tabulated 
pressures reflect measured quantities obtained at aortic arch of both patients. 
 
Cycle 
Number 
External 
Pressure 
Application 
(mmHg) 
Systolic 
BP 
(mmHg) 
Systolic 
Augmentation 
(mmHg) 
Systolic 
Augmentation 
(%) 
Diastolic 
BP 
(mmHg) 
Diastolic 
Augmentation 
(mmHg) 
Diastolic 
Augmentation 
(%) 
MAP 
(mmHg) 
MAP 
Augmentation 
(mmHg) 
MAP 
Augmentation 
(%) 
Pa
tie
nt
 1
 Baseline 0 82 -- -- 47 -- -- 59 -- -- 
1 37 91.6 9.6 11.7 51.1 4.1 8.7 64.6 5.6 9.5 
2 47 94.9 12.9 15.7 54.2 7.2 15.3 67.8 8.8 14.9 
3 57 97.3 15.3 18.7 57.1 10.1 21.5 70.5 11.5 19.5 
Pa
tie
nt
 2
 Baseline 0 117 -- -- 79 -- -- 92 -- -- 
1 69 127.2 10.2 8.7 84.5 5.5 7.0 98.7 6.7 7.3 
2 79 130.1 13.1 11.2 86.5 7.5 9.5 101 9 9.8 
3 89 127 10 8.5 85.6 6.6 8.4 98.9 6.9 7.5 
 
 
All systolic and diastolic pressures are functions of aortic pressure obtained from a 
catheter mounted pressure transducer placed in the aortic arch of both patients. Increases in 
aortic pressures were noticeable in patient pressure waveforms generated from the pressure 
transducer floating in the aorta. Figure 16 illustrates the increase in aortic pressures due to 
external pressure application for patient 1 and patient 2 during a selected inflation cycles. 
Figure 17 illustrates the calculated aortic MAP augmentation during 1 inflation/deflation 
cycle for patient 2. 
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Figure 16: Sample pressure data from external pressure augmentation obtained 
during cardiac catheterization. A) Patient 1 during upstroke of external pressure 
application at 47 mmHg. B) Patient 2 during upstroke of external pressure application at 69 
mmHg.  
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Figure 17: Aortic MAP augmentation during 1 cycle for patient 2. 
 
 
4.2 Numerical Simulation Results 
 Figure 18 illustrates the percutaneous, magnetically levitated and rotated axial flow 
blood pump designed as the minimally invasive approach for augmentation of Failing 
Fontan hemodynamics. Over 900 numerical simulations were completed to optimize pump 
design and test pump performance, quantifying its effectiveness at augmenting flow and 
providing hemodynamic relief to Fontan patients. Simulations were conducted in 2 extra-
cardiac three dimensional models, an idealized TCPC and a patient specific TCPC 
generated from MRI data, investigating multifarious physiologic conditions including 
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combined IVC and SVC flow rates of 1 to 7.5 LPM, pulmonary arterial pressures (LPA 
and RPA) of 10 to 26 mmHg, and blood viscosities of 3.5cP, 5.0 cP, and 6.5cP. The follow 
sections detail the results from these simulations.  
 
Figure 18: Intravascular, magnetically levitated and rotated, axial flow blood pump. 
Pump is designed to provide a minimally invasive method to alleviate poor hemodynamic 
associated with Failing Fontan physiology.  
 
  
4.2.1 Pump Pressure Curves 
The pressure generation across the intravascular blood pump in the idealized TCPC 
model was determined for flow rates of 1 to 7.5 LPM and pump rotational speeds of 3000 
to 8000 RPM.  Figure 19 illustrates the hydraulic performance of the idealized TCPC 
model. Each data point is indicative of a steady state simulation at a specific flow rate and 
rotational speed. The pump delivered a range of pressure rises from 2 to 26 mmHg for 
these operating conditions. Additionally, pressure rise across the pump increased with an 
increase in rotational speed and decreased with an increase in flow rate, as to be expected. 
The pressure curves demonstrate the axial flow pump’s capabilities to provide acceptable 
pressure generation for the physiologic conditions.  
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Figure 20 compares the axial flow blood pump design with and without a set of 
diffuser blades located at the pump head.  The model with diffuser blades operated at 
reduced rotational speeds and generated more than twice as much pressure head across the 
pump. The pump with diffuser blades outperformed the pump without diffuser blades over 
both investigated units (flow rate and rotational speed) thus demonstrating an improvement 
to previous pump design work.  
Figure 19. CFD predictions of the hydraulic performance of the blood 
pump in the Idealized TCPC model. Pressure generation across the axial 
flow blood pump with impeller and diffuser blades. Simulations were 
completed with flow rates of 1 to 7.5 LPM, rotational speeds of 3000 to 
8000 RPM, and pulmonary arterial pressure set at 14 mmHg. 
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The diffuser blades increased pressure rise across the pump by reducing the fluid 
velocity thus transferring energy to pressure as in accordance with conversation laws. 
Figure 21 below illustrates the reduction in fluid velocity of blood flow exiting the 
impeller region and associated total pressure contour across the pump. Fluid velocity 
augmented by rotating impeller blades was reduced by the counter orientated rotating 
diffuser blades, transferring the velocity augmentation to pressure augmentation.  
Figure 20: CFD predictions of the hydraulic performance of the blood pump in 
the Idealized TCPC model. Two blood pump designs were considered. One model 
had the protective cage, catheter, and an impeller blade set only. The other model 
included a set of diffuser blades at the outflow of the pump. Flow rates of 1 to 6.5 
LPM were simulated for a wide range of rotational speeds of 4000 to 12,000 RPM.  
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Figure 22 illustrates pressure rise across the pump and pressure decrease at the IVC 
inlet as a function of pump rotational speed for the idealized TCPC.  Conditions for the 
comparison included flow rates of 1 to 4 LPM for rotational speeds of 2000 to 6000 RPM 
and pulmonary pressures of 10 to 26 mmHg. The IVC pressure is decreased as the pump is 
rotated faster, as would be expected. Additionally, higher arterial pressures lead to higher 
IVC pressures. 
 
 
Figure 22: Pressure rise across the axial blood pump in the idealized TCPC model and the 
IVC pressure as a function of increasing rotational speed. (A) This graph illustrates the trends 
of the pressure rise across the pump to increase with increasing rotational speeds, as would be 
expected. In addition, the pressure rise is lower for a higher flow rate at a given rotational speed, 
as would theoretically be expected. (B) This graph shows the impact of the blood pump on the 
IVC pressure on the inlet side of the pump as a function of increasing rotational speed and 
pulmonary arterial pressures at a blood flow rate of 5 LPM.  
 
 
Figure 21: Diffuser blades reduce fluid velocity and increase pressure.  
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The pressure generation across the intravascular blood pump in the anatomical 
patient specific TCPC model was determined for flow rates of 1 to 5 LPM and pump 
rotational speeds of 2000 to 5000 RPM.  Figure 23 illustrates the hydraulic performance of 
the anatomical TCPC model. The pump delivered a range of pressure rises from 1 to 7 
mmHg for these operating conditions. As observed in the idealized TCPC model, pressure 
rise across the pump increased with an increase in rotational speed and decreased with an 
increase in flow rate.  
 
 
 
Figure 24 demonstrates the influence of pump rotational speed on IVC inlet 
pressure for the anatomical TCPC model. As expected, pressure at the IVC inlet decreased 
as a function of increased pump rotational speeds. Parameters for these results included 
Figure 23: CFD predictions of 
the hydraulic performance of 
the blood pump in the Patient 
Specific TCPC model. Pressure 
generation across the axial flow 
blood pump with impeller and 
diffuser regions. Data represents 
simulations conducted at 
LPA=RPA=14 mmHg for flow 
rates of 1 to 5 LPM and pump 
rotational speeds of 2000 to 5000 
RPM. 
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flow rates of 1 to 5 LPM, pump rotational speeds of 2000 to 5000 RPM and 
LPA=RPA=14mmHg.  
 
 
  
 
 
4.2.2 Flow Profile 
 Careful analysis of flow fields are critical to the development of a axial flow pump 
designed for augmentation of the cardiovascular system. Irregular flow patterns such as 
vortices, eddies, and flow stagnation could increase blood exposure to high levels of shear 
stress activating thrombolytic factors or erythrocyte hemolysis. Figure 25 below illustrates 
the flow profiles for the axial flow blood pump with and without diffuser blades. The 
streamlines for both pump models were generated at a fluid flow rate of 3.5 LPM and 
pump rotational speeds of 5000 RPM. The inclusion of the diffuser blades accomplished a 
reduction in swirling and vortices at the pump outlet, but did not complete eliminate the 
irregular flow. Additionally the streamlines of the pump model with a diffuser exhibit 
Figure 24: Pressure rise across the axial blood pump in the patient specific TCPC model and the 
IVC pressure as a function of increasing rotational speed. (A) Pressure rise across the pump to 
increases with increasing rotational speeds, as would be expected. Pulmonary arterial pressures were set 
to 14mmHg for these comparisons. (B) This graph shows the impact of the blood pump on the IVC 
pressure on the inlet side of the pump as a function of increasing rotational speed and pulmonary arterial 
pressures at a blood flow rate of 5 LPM. 
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lower particle velocities at the outlet as compared to the pump model without a diffuser, 
indicating a reduction in fluid velocity and thus an increase in pressure as confirmed in the 
previous section.  
 
Figure 25: Reduction in Vorticity due to diffuser blades. The diffuser blades are able to 
redirect flow at the outlet and reduce the outflow vorticity, however not able to eliminate 
the flow swirl as intended.  
 
Fluid streamlines through the idealized TCPC are displayed in Figure 26 and 
anatomical patient specific TCPC model 1 with and without the intravascular blood pump 
are displayed in Figure 27.  The fluid streamlines correspond to operating conditions of 
pulmonary pressures of 14 mmHg, blood flow rate of 3.5 LPM, and pump rotational speed 
of 5000 RPM. Strong rotational flows were found at the outlet of both pump models, 
dissipating some through the pulmonary arteries. 
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Figure 26: Fluid streamlines for the idealized TCPC model with and without the 
intravascular pump. Idealized model streamlines without pump (A) display high velocity 
turns at the outer boundaries of caval veins and pulmonary arteries connection points. (B) 
Velocity increases at IVC outlet due to axial flow pump. 
 
 
Figure 27: (A) Fluid streamlines for patient specific TCPC model without the 
intravascular blood pump. Lowest fluid velocities are observed at the inner boundaries of 
the TCPC. (B) Increased fluid particle velocities observed due to axial flow blood pump.  
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4.2.3 Scalar Stress Distributions 
Scalar Stress represents a calculated weighted average of the shear and normal 
stresses and is useful for determining the level of blood trauma during pump operation. 
Figure 28 displays the scalar stress distribution through the intravascular cavopulmonary 
pump model along the rotor hub. At the design point, the highest fluid stresses of 125 Pa 
were estimated to exist along a small regional surface area at the leading edge of the 
impeller blades and more substantially along the impeller blade tips.  
 
Similarly, Figure 29 illustrates the scalar stress levels along the surfaces of the 
protective cage of filaments. The magnitude of the scalar stress remained below 120 Pa 
with the highest stress regions in closer proximity to impeller blade tips. These regions of 
high scalar stress are attributed to the interaction between the impeller blade and cage 
filaments.  
Figure 28: Scalar stress estimations on 
the impeller and diffuser hub surfaces. 
The magnitude of the scalar stress 
remained below 125 Pa with the highest 
stress regions along the impeller blade tip 
surface. Higher stresses were predicted at 
the blade tip when in closer proximity to 
the protective cage filaments. 
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4.2.4 Blood Viscosity Effects 
In consideration of the target patient population and their varying blood viscosity 
values, Figure 30 illustrates the results of the viscosity study performed on the Idealized TCPC 
model and the impact on pump performance. It was determined that IVC pressure varied little 
for higher viscosity values at lower rotational speeds. This sensitivity appeared to increase to 
approximately 8.5% at 5000 RPM. The pressure rise across the pump was also not sensitive to 
increasing viscosity values at all rotational speeds with a deviation averaging 4.6%. 
Figure 29: Scalar stress estimations on 
the cage filament surfaces. The 
magnitude of the scalar stress remained 
below 120 Pa with the highest stress 
regions of closer proximity to impeller 
blade tips.  
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4.2.5 Quasi-Steady State Study 
In order to detect the optimal axial rotational orientation of the impeller and 
diffuser blades a quasi-steady state study was performed for the cavopulmonary blood 
pump. Figure 31 illustrates the computational predictions from the quasi-steady analysis of 
the diffuser blades and their impact on pressure generation as a function of rotation 
position. Thirty simulations were completed for rotational increments of 3 degree. This 
study was performed at 5000 RPM and 2 LPM. According to the numerical findings, the 
Figure 30: Effect of Blood 
Viscosity on Pressure in the 
IVC and Pressure Rise across 
the Pump as a function of 
pump rotational speed. (A) 
Adjustments to IVC pressure due 
to the pump rotational speeds 
varied little for higher fluid 
viscosity values, indicating the 
versatility of the pump to 
accommodate a range of possible 
patient conditions. (B) Pressure 
rise across the pump was 
maintained over all rotational 
speeds without reduction or 
measurable change due to 
increasing viscosity. 
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diffuser blades having a rotational position of 12 degree produced the largest pressure 
generation across the pump. The predicted improvement in pressure rise was found to be 
6%.  The diffuser blades having a rotational position of 57 degree generated the lowest 
pressure across the blood pump. A pressure reduction at the 57 degree position was found 
as compared to all other rotational positions. In comparison of the pressure generation at 
the initial design position at 0 degree (10 mmHg), the 57 degree rotation of the diffuser 
blades resulted in a pressure generation decrease of 37% (6.3 mmHg). 
 
 
4.2.6 Blood Damage Analysis 
In addition to the quasi-steady study, a blood damage analysis was conducted to 
consider the potential for hemolysis from blood contacting the pump. This approach 
releases massless, inert particles at the inlet and tracks using streamlines their exposure 
time to fluid stresses. It uses a power law relationship between the scalar stress values and 
the exposure time to estimate an accumulated blood damage index for each particle. The 
blood damage analysis was completed on the idealized TCPC model to approximate the 
level hemolytic and thrombotic factors incurred due to blood contact with the intravascular 
Figure 31:  Quasi-steady study of the 
rotational impact for the diffuser 
blades. This study was performed at 
5000 RPM and 2 LPM. The diffuser 
blades having a rotational position of 
12 degree produced the largest 
pressure generation across the pump. 
The diffuser blades having a rotational 
position of 57 degree generated the 
lowest pressure across the blood pump. 
12o 
57o 
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blood pump. Figure 32 displays the results of the numerical blood damage analysis. Three 
cases with a pump flow rate of 3.5 L/min were considered in this analysis: 1) a fluid viscosity 
of 5 cP and rotational speed of 5000 RPM, 2) a fluid viscosity of 3.5 cP and rotational speed of 
5000 RPM, and 3) a fluid viscosity of 3.5 cP and rotational speed of 4000 RPM. Table 10 lists 
these cases and their corresponding results, as discussed in the subsequent sections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Blood damage indices and particle residence times for the idealized TCPC 
model. Intravascular blood pump operating conditions, fluid viscosities, and LPA/RPA 
arterial pressures as specified in Table 4. (A) Case I, (B) Case II and (C) Case III results.  
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Table 10:  Blood damage analysis details and finding for the Intravascular 
Axial flow blood pump and the Idealized TCPC model.   
 
 
4.2.7 Energy Gain 
In addition to the blood damage analyses, energy losses due to the cavopulmonary 
connection are of general concern due to associated pathophysiologies deriving from the 
loss of the pulmonary ventricle. A simplified control volume approach was used to 
calculate the hydraulic energy of the both TCPC models with and without the axial flow 
blood pump placed in the IVC. Figure 33 demonstrates the energy gain due to mechanical 
assistance of the idealized TCPC with the pump design having an impeller and diffuser 
blade set. These simulations occurred at an operating condition with left and right 
pulmonary arterial pressures of 14 mmHg, a fluid viscosity of 3.5 cP, a range of flow rates 
from 1 to 3.5 L/min, and two rotational speeds of 4000 and 5000 RPM. In comparison to 
the energy loss associated with the idealized TCPC without mechanical support, the 
predictions indicated that the use of the pump to mechanically augment pressure in the 
IVC increases the hydraulic energy of the TCPC as a function of both increasing rotational 
speed and flow rate.  
Blood Damage 
Case Number 
Flow Rate (LPM) Rotational Speed (RPM) Fluid Viscosity (cP) Number of Particles Mean Damage Index Maximum Damage Index Mean Residence Time(sec) Maximum Residence Time(sec) 
 
Case 1 
 
 
3.5 
 
5000 
 
5 
 
 
350 
 
0.110% 
 
0.990% 
 
0.2724 
 
0.3740 
 
Case 2 
 
3.5 
 
5000 
 
3.5 
 
 
350 
 
0.130% 
 
0. 800% 
 
0.3754 
 
0.3990 
 
Case 3 
 
 
3.5 
 
4000 
 
3.5 
 
350 
 
0.0549% 
 
0.280% 
 
0.4222 
 
0.5160 
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Figure 33: Energy Gain due to mechanical assistance of the idealized TCPC with a 
blood pump in the IVC. Mechanical assistance of the IVC pressure enhanced the 
hydraulic energy within the TCPC as compared to conditions without pump support. 
 
Figure 34 demonstrates the energy gained due to mechanical assistance with the 
pump as compared to the energy lost due anatomy and physiology in the patient specific 
TCPC model. These calculations were made for the following operating conditions: left 
and right pulmonary arteries at 14mmHg, flow rates from 1 to 4 LPM, and pump rotation 
speed of 5000 RPM. As observed in the idealized energy calculations, the introduction of a 
circulatory assist device to the Fontan anatomy significantly increases the hydraulic energy 
of blood flow thus mitigating the loss from a lack of pulmonary ventricle. 
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Figure 34. Energy Gain due to mechanical assistance of the patient specific TCPC with a 
blood pump in the IVC. Mechanical assistance of the IVC pressure enhanced the hydraulic 
energy within the patient specific TCPC as compared to conditions without pump support. 
 
 
4.3 Chapter Summary 
 Based upon the results of numerical simulations of the two pump models and two 
extra-cardiac Fontan models, the intravascular axial flow blood pump was optimized in 
design as follows: an impeller with 3 counterclockwise helically wrapped blades, a diffuser 
region with 4 clockwise helically wrapped blades at a 12o offset to the impeller, and 
protective cage with 5 filaments. The optimized pump generates pressure rises of 2 to 25 
mmHg for flow rates of 1 to 7.5 LPM and rotational speeds of 2000 to 8000 RPM, reduces 
irregular flow perturbations at the pump outlet, and demonstrates low probabilities for 
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erythrocyte damage. Table 11 outlines the design specifications and numerical results of 
the optimized intravascular, axial flow blood pump.   
Table 11: Summary of Axial Flow Blood Pump Design Specifications and Results   
Design Specifications and Investigations Numerical Results 
Impeller Blade Count 3 
Impeller Blade Orientation Counter-clockwise 
Diffuser Blade Count 4 
Diffuser Blade Orientation Clockwise 
Impeller-Diffuser Optimal Rotational Offset 12o 
Axial Flow Blood Pump Pressure Generation 1 - 26 mmHg 
Blood Flow Rates 1 - 7.5 LPM 
Pulmonary Arterial Pressure 10 -26 mmHg 
Pump Rotational Speed 1000 - 8000 RPM 
Maximum Scalar Stress 125 Pa 
Maximum Blood Damage Index 0.99% 
Mean Blood Damage Index 0.10% 
Maximum Residence Time 0.516 sec 
Mean Residence Time 0.35667 sec 
Maximum Energy Gain (Idealized) 45 mW 
Maximum Energy Gain (Patient Specific) 27 mW 
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CHAPTER 5 DISCUSSION 
 
Fontan and Baudet introduced the total right heart bypass in 1968 [86, 87]. Decades 
prior to their original description, at least 40 different experimental procedures to bypass 
the right heart provided evidence that venous pressure alone could act as the driving force 
for blood flow into pulmonary circulation. The current treatment paradigm for patients 
with univentricular physiology is a staged surgical palliation, leading to a Fontan 
conversion. Several modifications to the Fontan have developed over time with the TCPC 
providing a direct connection from the superior and inferior vena cava to the pulmonary 
arteries. In the absence of a pulmonary ventricle, the blood traveling through the Fontan 
circulation experiences a loss of energy with minimal to no pulsatility as it flows through 
the pulmonary circulation [1-4, 10, 11, 15, 65, 88]. Secondary pathologies due to the new 
“man-made” physiology include reduced preload, diminished exercise capacity, 
supraventricular arrhythmias, protein losing enteropathy, aortopulmonary and veno-veno 
collateral vessels. It has been theorized that the long-term effects of the Fontan paradox 
(caval hypertension and relative pulmonary hypotension) can be reversed through 
mechanical support [22, 49, 61].  
This thesis documented the methods, materials, and results for two mechanical 
cardiovascular assist devices designed to augment the hemodynamics of adolescent and 
adult Fontan patients. A non-invasive method for circulatory support provided via 
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counterpulsation external pressure technology was described in Chapter 2 and the results 
were outlined is Chapter 4. Likewise, the minimally invasive method using an 
intravascular axial flow blood pump inserted into the IVC was described in Chapter 3 with 
numerical simulation results outlined in Chapter 4. Discussions for each method of 
mechanical cardiovascular assist are in the sections below. 
 
5.1 Non-invasive External Pressure Augmentation 
 
The goal of the non-invasive cardiovascular assist modality was to develop and 
design an innovative non-invasive medical device for the prevention and/or treatment of 
pathological implications in postoperative Fontan patients adjusting to their new “man-
made” physiology. This device would provide cardiovascular assistance to patients through 
the augmentation of systemic blood flow to the pulmonary arteries, thus increasing venous 
return and pulmonary perfusion, and reducing cardiac afterload. The device operates 
through the medium of external pressure application to the lower limbs and abdomen, 
forcing forward propulsion of blood towards the heart and pulmonary circulation, 
analogous to muscular contractions during exercise. For this thesis clinical trials were 
completed utilizing retrofitted MAS trousers as the channel for external pressure 
augmentation. Positive results from the clinical trials serve as the clinical feasibility study 
for development of a novel external cardiovascular assist device for patient use at home.  
Subject recruitment began immediately after we received Virginia Commonwealth 
University IRB approval in January 11, 2009 (VCU IRB #HM11906).   
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 Two patient trials were completed during the first year of the IRB approved clinical 
investigation. Clinical trial subject population was limited due to exclusion criteria and 
reduced qualified candidate pool of a unique cohort of cardiovascular defects. The first 
clinical trial occurred February 19, 2009 with Dr. William Moskowitz conducting the 
cardiac catheterization on a 37 year old female single ventricle patient with a TCPC extra-
cardiac Fontan anatomy. Results indicated an increase in pressure of approximately 4 -15 
mmHg for systolic and diastolic pressure measured in the aortic arch. As illustrated in 
Figure 14, trends in patient 1 data demonstrate almost a linear correlation with increases in 
external pressure application providing evidence that the application of external pressure 
increased venous pressures which translated to an increased of blood flow to pulmonary 
circulation and subsequently the aortic arch.  
 In contrast to patient 1, patient 2 did not demonstrate the expected linear correlation 
between the external pressure application and resulting influence in aortic blood pressure. 
Several considerations and speculations can be offered as explanation for the unexpected 
trends exhibited by patient 2. The second clinical trial occurred on October 6, 2009 with 
Dr. William Moskowitz conducting the cardiac catheterization on a 24 year old male single 
ventricle patient with a classical Fontan with the right atrium is preserved, also known as 
an intra-atrial Fontan. During the clinical trial, the abdominal section was neglected due to 
the patient’s medical history of sleep apnea posing as exclusion criteria for any external 
pressure application with possible respiratory constriction affects.  Hepatic vessel 
compliance during pressure application to the lower limbs may account for a portion of the 
pressure dissipation downstream of the heart. The patient’s Fontan anatomy may have also 
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contributed to the reduced response of external pressure application due to compliance of 
the intact right atrium expanding to accommodate the increased volumetric blood flow. 
Additionally during the catheterization, observations were made with patient respirations 
and correlations to patient pulmonary arterial pressures. During deep sleep it was noted 
that the patient’s inspiration and expiration had discernable affects on pulmonary arterial 
pressures, thus insinuating observed pressure augmentation to aortic blood pressure may 
not be independent of respiratory cycle. 
 
 
5.2 Minimally Invasive Intravascular Blood Pump 
 
In support of the development of a minimally invasive cavopulmonary assist 
device, this thesis outlined the results of numerical analyses on an intravascular blood 
pump placed in Fontan TCPC models. The mechanical circulatory device is a collapsible, 
percutaneously inserted, axial flow blood pump designed to function as a bridge-to-
transplant or bridge-to-recovery for adult Fontan patients. Description and placement of 
the pump can be found in Figures 9 with a full detail presented in previous chapters.  
Extensive numerical studies were conducted to test pump performance in an 
idealized TCPC model and a patient specific TCPC model. Left and right pulmonary 
arterial pressures were examined at five pressure points from 10 mmHg to 26 mmHg, blood 
viscosities from 3.5cP to 6.5 cP, and pump rotational speeds from 1000 RPM to 8000 
RPM. The pump demonstrated hydraulic performance as quantified by pressure 
generations of 1 to 25 mmHg over flow rates of 1 to 7.5 LPM. This range of pressure rises 
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and flow rates is sufficient to support an adolescent and adult Fontan patient. Hydraulic 
performance curves were characteristically consistent for varying rotational speeds.  
Fluid viscosity influences were found to be minimal with greater effects found at 
higher rotational speeds as demonstrated in Figure 30 in chapter 4. The low influence of 
higher fluid viscosities on pump performance is important since a majority of Fontan 
patients are polycythemic, thus having a wide range of blood hematocrits. A versatile 
pump design that is not subject to performance losses over a range of blood hematocrits is 
advantageous for Fontan patients. 
Blood damage analyses were performed on three cases, all of which resulted in a 
maximum damage index of less than 1% and maximum residence time of less than 0.52 
seconds indicating a low probability of blood damage due to interaction with the pump. 
Two cases were performed off design point of the pump reflecting the position that the 
pump will often function off ideal design parameters. The majority of tracked particles 
indicated an even lower probability of damage as demonstrated in Figure 32 and Table 10 
in Chapter 4. The maximum blood damage indices also predict a very low N.I.H for these 
operating conditions examined. Blood pumps are designed to maintain an N.I.H level 
below 0.005 g/100L for clinical use. The predicted N.I.H values remained one to two 
orders of magnitude lower than the cutoff limit for clinical use. Table 12 below outlines 
the results from the blood damage analyses as compared to selected clinically available 
adult rotary blood pumps. Estimations indicate that centrifugal blood pumps have damage 
indices of 4% to 6% [79] and axial blood pumps have higher indices, ranging from 19% to 
40% [61].  Based on this comparison and the number of particles used in this study, these 
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results suggest that a majority of the tracked particles have a low probability of damage, 
however blood bag experimentation must be performed to quantify the levels of hemolysis 
for this intravascular blood pump.  
  
 
Table 12: The comparison of blood damage indices and N.I.H values for selected 
adult rotary blood pumps.[51, 61, 89-92]  
Pump Type N.I.H. (g/100L) Damage Index (%) 
Valvo Pump Axial 0.030 200 
MicroMed-DeBakey Axial 0.0028 19 
Biomedicus BP-80 Centrifugal 0.0007 5 
Berlin Incor I Axial 0.006 40 
HeartMate II Axial 0.005 33 
Intravascular Pump* Axial --- 1 
 
 
To analyze the interactive dynamics between the pump and the TCPC, we 
calculated the energy of the total system using a simplified control volume approach.  This 
technique has been commonly used by researchers and clinicians to maximize surgical 
optimization of the TCPC and elucidate new surgical strategies to mitigate hydraulic 
energy losses [65]. Under conditions where no artificial right ventricle or subpulmonary 
power source exists, such as those present in the Fontan physiology, energy losses 
invariably occur with blood flow in the TCPC and subsequent flow into the LPA and RPA.  
Previous studies found the energy losses (i.e. power loss) in the TCPC to increase due to 
higher flow rates, lower limb exercise, dramatic changes in the geometry of the 
anatosmoses, and lack of caval offset [93].  By incorporating a blood pump into the IVC, 
energy augmentation is observed, rather than hydraulic losses. This positive augmentation 
of energy due to the pump in the IVC is the intended result and may translate into an 
improvement in venous return and cardiac output for Fontan patients.  In conjunction with 
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surgical optimization of the TCPC, the introduction of periodic or short-term 
cavopulmonary assist may serve as a viable, long-term, clinical management strategy for 
Fontan patients.  
Figure 33 in Chapter 4 illustrates the energy losses of the idealized TCPC without a 
pump in the IVC in comparison to the energy gains of the idealized TCPC with the 
intravascular pump (impeller and diffuser blade set) in the IVC. Pump rotational speeds of 
4000 RPM and 5000 RPM were examined to determine the energy augmentation in the 
idealized TCPC.  A steady increase in energy as a function of flow is observed from 1 to 
3.5 L/min for the 4000 RPM operating conditions.  Upon reaching 4 L/min, the energy 
performance curve at 4000 RPM ceases to increase in slope; the inherent hydraulic losses 
from this higher flow rate through the idealized TCPC and the lower head produced by the 
pump begin to inhibit energy augmentation.  For the 5000 RPM operating condition, the 
pump is able to continuously improve energy gains over the entire 1 to 4 L/min flow range.  
Similar trends were observed for the patient specific TCPC Fontan model. The energy gain 
from the pump in the patient specific TCPC model peaked under 30mV with similar linear 
trends indicating that increase in flow rates at give pump RPM would result in increased 
energy gain.  
In examining the outflow conditions of the pump, a rotational component of the 
flow was predicted by the computational analysis. The introduction of a diffuser region 
consisting of a hub with 4 clockwise helically wrapped blades demonstrated a reduction in 
vorticity at the outlet of the pump as compared to previous models without a diffuser 
region. Figure 25 illustrates the diminution of rotational fluid flow at the outlet region of 
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the pump. Complete elimination of irregular flow patterns were not achieved thereby 
requiring the above discussed analyses of energy gain and blood damage indices. Despite 
the rotational flow component, power or energy enhancement was achieved, and low blood 
damage indices were predicted. Additional design work will be performed to minimize this 
flow rotational and straighten the blood flow leaving the pump. 
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CHAPTER 6 FUTURE WORK AND CONCLUSIONS 
  
 
6.1 Limitations and Future Work 
 Previous chapters discussed two novel approaches for the development of 
mechanical circulatory devices for Fontan patients. A non-invasive method using external 
pressure augmentation to the lower limbs demonstrated notable increases in systolic and 
diastolic blood pressures for in two patients. A minimally invasive method using a 
percutaneously inserted, intravascular blood pump computationally demonstrated 
acceptable pressure generations to augment the Failing Fontan hemodynamic. Both 
modalities show promise in the clinical support and treatment of Fontan patients: the 
pressure pants as long-term preventative support and axial flow blood pump for short term 
bridge support. Study limitations are discussed in this chapter along with issues to be 
addressed in future work.  
6.1.1 Pressure Garment 
 A considerable limitation to thesis work with regard to the pressure garment 
clinical trials was the lack of test subject population. During the year and a half time frame 
of the VCU IRB approved clinical trials, only two patients successfully met the criteria and 
participated in the study. Factors influencing the deficiency in subject population include 
the diminutive single ventricle Fontan cohort perpetuated by a single intuitional 
investigation and extensive exclusion criteria inclusive of several secondary pathological 
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conditions common to Fontan patients. Future clinical studies for continued development 
of the pressure garment will address these limitations by seeking multi-institutional clinical 
trials. 
During development of the clinical external pressure augmentation protocol several 
inflation/deflation intervals and timings were considered. Interval cycles excogitated for 
the clinical trial included cardiac cycle synchronization, respiratory cycle synchronization 
and constant interval based. Research indicates that the majority of clinical external 
pressure pulsation devices are synchronized to the patient’s cardiac cycle thus requiring 
more advanced technology and a nurse or technician to monitor and operate the device for 
proper synchronization. Having stated our predispositions of EECP delivery with 
accordance to synchronization protocol in Chapter 2, it was inferred that counterpulsasive 
therapy less synchronization will also demonstrate beneficial results. This assumption was 
strongly supported by the results this study in addition to the reviewed literature. 
Discrepancies arise, however, when attempting to decipher the degree of assistance 
provided by counterpulsation administered at a basal rate unlinked to a patient’s cardiac 
cycle. If future work includes investigation of cardiac synchronization, it is expected that 
cardiac synchronization is significant to the level of augmentation provided by 
counterpulsation, however the occurrence of such augmentation is independent of 
synchronization.  
Respiratory cycle synchronization was also considered. Chest wall expansion during 
inhalation and subsequent depression during exhalation influence cardiac filling and 
ejection. Upon deep inhalation, the second heart sound can split providing audible 
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evidence of a delay between the closing of the pulmonary and aortic valves. Though 
respiratory synchronization effects would have been interesting to investigate, it was not 
included due to the overall goal of developing a therapeutic device for patients to use at 
home, thus requiring a simpler model. However, due to correlating respiration cycle and 
pulmonary arterial pressures observations made during the second patient’s clinical trial, 
continued development of an external mechanical cardiac assist device would include 
respiratory cycle synchronization analyses.  
 Based upon the need for a simple device designed to augment venous flow a 
constant interval cycle was determined to be the favorable timing for pressure garment 
inflation and deflation. The constant interval cycle was conducted as a square wave, with 
inflation demonstrated as the highpoint when the pressure is applied and deflation as the 
lowpoint when the pressure is removed. An ideal square wave interval cycle would 
demonstrate precision in holding the pressure at a specific target and instantaneous 
inflation and deflation. Though based on the ideal, the clinical trial conducted with 
retrofitted medical anti-shock trousers resembled more of a trapezoidal wave with sloping 
increases and decreases in pressure during cycles.  Additionally, during the inflation hold 
periods loss of pressure may be exhibited do to leaks within the pressure pant system. With 
these limitations considered, it was determined that for the purpose of augmenting venous 
blood flow to the heart, slight fluctuations in external pressure are inconsequential and thus 
do not contravene the use of a constant interval cycle nor discount the integrity of trial 
results. However future work with the pressure garment will not only reconsider the before 
90 
mentioned synchronization affects but also reduce pressure loses during inflation holds by 
identifying and subsequently rectifying system leaks.    
The VCU/MCV catheterization laboratory employs SIEMENS (Siemens 
Corporation, New York, NY) technology. The current software package conducts real-time 
analyses and stores user defined values or pressure waveform moments at a defined time. 
Continual recording of pressures for analysis at a later time is outside the software 
capabilities thus limiting the view of external pressure augmentation influence on patient 
hemodynamics. Additionally, the software is confined to output averaged pressures for 
selected waves and incapable of outputting discrete data, greatly influencing the accuracy 
of data analyses.  
 
6.1.2 Intravascular Blood Pump 
This thesis work on the intravascular blood pump has a number of limitations that 
must be addressed during the next stage of development. The boundary conditions as 
specified are for steady flow analyses; transient flow simulations and fluid structure 
interaction (FSI) studies with varying inlet and outlet impedances, vessel compliance, and 
lung compliance would provide more accurate information about the interactive dynamics 
between the physiology and the blood pump. A detailed turbulence model study would 
also generate valuable insight into the fluid dynamics.  
The manufacturing of three-dimensional models of the idealized Fontan TCPC 
anatomy and patient specific TCPC anatomy with inclusion of the pump prototype in the 
IVC is currently underway. These models will allow for laser flow measurements and 
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hydraulic performance testing to take place and to validate numerical predictions from this 
thesis.  
The blood damage analyses conducted with the idealized TCPC model did not 
consider heat transfer, platelet activation, and transient effects in the fluid stresses due to 
blade rotation. Additionally, the blood damage analysis uses a power law equation 
generating overestimations in the levels of hemolysis. The overestimation, however, allows 
pump design to err on the side of caution. Hemolysis testing using physical prototypes 
would provide more realistic confirmation of actual trauma levels. 
 
6.2 Conclusions from Research 
This thesis presented two novel approaches for the development of a mechanical 
cardiovascular assist device for patients with Fontan physiology. The first approach 
suggested the design of a noninvasive mechanical device which would augment Fontan 
hemodynamics via external pressure application to the lower limbs and abdomen. This 
thesis presented the results of a VCU IRB approved clinical trial for feasibility studies and 
provided proof of concept for the design of a novel pressure garment. The pressure 
garment is intended for patient use at home at their convenience to alleviate cardiac 
workload providing hemodynamic relief. Results from patient trials indicate external 
application to the lower limbs and abdomen of as little as 10 mmHg below baseline 
diastolic may be enough to augment Fontan pressures and improve hemodynamics 
functioning in a preventative and sustaining manner.  
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The second approach involved the design of a minimally invasive, percutaneously 
inserted, intravascular blood pump design for placement in the IVC. This collapsible axial 
flow blood pump is designed with a 3-bladed impeller, 4-bladed diffuser, and radially 
arranged cage filaments serving as touchdown surfaces to protect the vessel wall from 
rotating components.  This thesis presented the numerical analyses of the interactive fluid 
dynamics between the cavopulmonary connection and a mechanical blood pump. The 
pump would serve as a bridge-to-transplant, bridge-to-recovery, or bridge-to-surgical 
reconstruction. A pressure augmentation of as little as 2 to 5 mmHg may be sufficient to 
stabilize and reverse hemodynamic deterioration in Fontan patients. Computational 
predictions indicate the blood pump would augment pressure acceptably in both the 
idealized TCPC and patient specific TCPC models and result in a hydraulic energy boost 
or gain for a range of viscosity values, LPA and RPA pressures, flow rates, and pump 
rotational speeds. These results support the continued design and development of this 
cavopulmonary assist device, building upon previous numerical work and future 
experimental testing.  
Both modalities that were evaluated in this thesis project showed tremendous 
promise to potentially support Fontan patients in the acute and long-term clinical setting. 
The designs of both modalities will evolve over time, ultimately leading to two viable 
therapeutic options for Fontan patients and addressing a significant human health problem. 
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APPENDIX A: MAST STUDY PROTOCOL 
 
MAST Study Protocol: 
 
1. After obtaining consent, place patient supine in MAST garment. MAST are not 
inflated. 
2. Place blood pressure cuff, pulse oximeter, standard ECG leads on patient. Insert 
catheter according to VCU protocol for cardiac catherization.  
3. Obtain and record baseline measurements onto data sheet. Based upon the patient’s 
diastolic pressure, determine three pressure levels to evaluate: 
1st Pressure level = (Diastolic BP) – 10 mmHg 
2nd Pressure level = (Diastolic BP) 
3rd Pressure level = (Diastolic BP) + 10 mmHg 
4. Administer the first pressure level with the following procedure: 
* Note: Clinical Measurements should be ongoing during this time. 
1. Use pump to inflate MAST garment to 1st pressure level. 
2. Hold pressure for 10 – 15 seconds. 
3. Release pressure valve and deflate pants.  
4. Hold deflated for 10 – 15 seconds.  
5. Repeat cycle 5 times. 
6. During the 5th cycle, reassess patient’s vital signs prior to 
deflation.  
7. Conclude after 5 minutes of Counterpulsation cycles.  
8. Allow patient to rest for 3-5 minutes.  
5. Administer the second pressure level with the following procedure: 
* Note: Clinical Measurements should be ongoing during this time. 
1. Use pump to inflate MAST garment to 1st pressure level. 
2. Hold pressure for 10 – 15 seconds. 
3. Release pressure valve and deflate pants.  
4. Hold deflated for 10 – 15 seconds.  
5. Repeat cycle 5 times. 
6. During the 5th cycle, reassess patient’s vital signs prior to 
deflation.  
7. Conclude after 5 minutes of Counterpulsation cycles.  
8. Allow patient to rest for 3-5 minutes.  
6. Administer the third pressure level with the following procedure: 
* Note: Clinical Measurements should be ongoing during this time. 
1. Use pump to inflate MAST garment to 1st pressure level. 
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2. Hold pressure for 10 – 15 seconds. 
3. Release pressure valve and deflate pants.  
4. Hold deflated for 10 – 15 seconds.  
5. Repeat cycle 5 times. 
6. During the 5th cycle, reassess patient’s vital signs prior to 
deflation.  
7. Conclude after 5 minutes of Counterpulsation cycles.  
8. Allow patient to rest for 3-5 minutes.  
7. After the patient rests for 5 minutes, reevaluate baseline vital signs.  
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APPENDIX B: RESEARCH SUBJECT CONSENT FORM  
 
 
RESEARCH SUBJECT INFORMATION AND CONSENT FORM 
 
 
TITLE OF RESEARCH: Clinical Measurement of Pressure Augmentation in the 
Systemic Venous Circulation using Medical Anti-Shock Trousers 
 
 
VCU IRB PROTOCOL NUMBER: 
 
 
INVESTIGATORS:  
Principal Investigator: Amy Throckmorton, Ph.D. 
Sub/Co-Investigator: William B. Moskowitz, M.D. 
Sub/Co-Investigator: Scott D. Gullquist, M.D. 
Student: Sonya Bhavsar, B.S. 
 
In ordinance with Federal Regulations for the Protection of Human Subjects section 
§46.116, “An investigator shall seek…consent only under circumstances that provide the 
prospective subject or the representative sufficient opportunity to consider whether or not 
to participate and that minimize the possibility of coercion or undue influence.” After 
carefully reading and understanding the information listed below, if you would like to 
participate in this research study please sign this consent form indicating your 
consent.  
 
This consent form may contain words or information that you do not understand.  Please 
ask one of the investigators to explain any words or information that you do not 
understand.  You may take home an unsigned copy of this consent form to think about or 
discuss with family or friends before making your decision. 
 
 
PURPOSE OF THE RESEARCH STUDY: 
The purpose of this research study is the test the effectiveness of routinely administered, 
non-invasive, external couterpulsation therapy via Medical Anti-Shock Trousers (MAS 
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trousers).  MAS trousers are pants that have an air filled gap inside of them; they function 
similar to blood pressure cuffs and can be inflated, only around the lower extremities or 
legs, as opposed to the upper arm. We will have you slip on the pants and then, using air, 
inflate these trousers. This will apply an external pressure to your legs in the form of light 
compression. In doing so, we will measure how this externally applied pressure may 
modify blood flow conditions in the circulation on the right side of your heart.  
 
You are being invited participate in this study because you have been diagnosed with 
single ventricle physiology or a closely related congenital heart defect and have already 
scheduled to receive an evaluative cardiac catheterization. Therefore, we can perform this 
study right before your cardiac catheterization in a safe and efficient manner. 
 
 
WHAT YOU WILL DO IN THE STUDY: 
Your participation in this study will last approximately 20 minutes  per session. We will 
acquire baseline vitals (blood pressure, heart rate, O2 saturation, respirations, right atrial 
pressure/central venous pressure, and pulmonary capillary wedge pressure) prior to 
inflating the pants with air, followed by three 3-5 minute sessions of incrementally 
increasing inflation levels. Your vital signs will be monitored throughout the session and 
again approximately 5 minutes after completion to obtain a second set of baseline vitals.  
 
Sample Procedural Timeline: 
 
1.) You will be placed in laying down, flat on your back. The MAS trousers will be 
applied.   
2.) We will apply a blood pressure cuff, pulse oximeter, and ECG leads. A catheter 
will be inserted into your femoral vein after the site has been numbed with local 
anesthetic.   
3.) Your first set of vital signs will be obtained. We will determine the three 
pressure intervals based upon your diastolic blood pressure.  
4.) The first pressure level will be administered. The MAS trousers will inflate and 
you will feel circumferential pressure applied to your lower extremities similar 
to a blood pressure cuff.  
5.) Your vital signs will be reassessed and the MAS trousers will deflate. You will 
rest for 3-5 minutes.  
6.) The second pressure level will be applied which is slightly higher than the 
previous.  
7.) Your vital signs will again be reassessed and the MAS trousers will deflate. 
You will rest for 3-5 minutes.  
8.) The third and final pressure level will be applied, your vital signs will be 
assessed and the MAS trousers will deflate.  
9.) After 5 minutes a second set of baseline vitals will be obtained.  
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Your participation in this study will last approximately 20 minutes. Approximately 10 
subjects will participate in this study.  
 
 
RISKS AND RISK REDUCTION: 
Prior to your enrollment in the study, an exclusion criteria was established to minimize any 
potential risks. Because you have been invited to participate in this study, you were 
determined to be at little to no risk.  
 
Due to the short time period of external pressure application, there is minimal to no risk.  
Deflation of the MAS trousers will be done methodically in order to maintain cardiac 
stabilization. Your vital signs will be carefully monitored and adjustments will be made as 
necessary. 
 
You will also be carefully monitored for any sign or symptoms of shock, which will be 
highly unlikely given the short duration (1-2 minutes) of externally applied pressure.  
Significant concern would arise if the duration of applied pressure exceeded 20 minutes, 
and the pressure was rapidly released, which will not occur during this study. Investigators 
and a full clinical staff in the cardiac catheterization lab will be present to ensure that the 
protocol will not be violated. 
 
During the procedure, we will determine whether positive results are being observed. If the 
observed results are not compliant with the hypothesized results, the procedure and study 
will be immediately terminated.  
 
All key personnel and resources normally found in the cardiac catheterization lab will be 
present and attentive during the course of procedure.  
 
 
BENEFITS TO YOU AND OTHERS: 
There is no guarantee that you will receive any medical benefits from being in this study. 
 
This is not a treatment study, and you may not receive any direct medical benefits from 
your participation. The information from this research study may lead to better treatment in 
the future for patients with single ventricle physiology or a closely related congenital heart 
defect.  
 
COMPENSATION: 
No compensation will be provided for this study. The knowledge gained from this study 
will be used to develop new MAS trousers or counterpulsation technology as a clinical 
management tool for patients with single ventricle physiology or a closely related 
congenital heart defect similar to yours.  
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CONFIDENTIALITY  
Adhering to IRB and Federal HIPPA regulations, only nonspecific information will be 
recorded during this study. This information includes patient age, sex, and diagnosis. 
 
Data being collected is for research purposes only. Your data will be identified by ID 
numbers, NOT names, and stored separately from medical records in a secured spreadsheet 
with the principle investigator.  
 
Access to all data will be limited to study personnel. A data and safety monitoring plan is 
established with accordance to IRB and Federal HIPPA regulations.  
 
 
COMPENSATION FOR INJURY: 
Virginia Commonwealth University and the VCU Health System have no plan for 
providing long-term care or compensation in the event that you suffer injury as a result of 
your participation in this research study. 
 
If you are injured or if you become ill as a result of your participation in this study, contact 
one of your investigators immediately. Your investigator will arrange for short-term 
emergency care or referral if it is needed. 
 
Fees for such treatment may be billed to you or to appropriate third party insurance.  Your 
health insurance company may or may not pay for treatment of injuries as a result of your 
participation in this study. 
 
 
VOLUNTARY PARTICIPATION AND WITHDRAWAL: 
Your participation in this study is voluntary. If you decide to not participate in this study, 
you will not suffer any penalty or loss of benefits to which you are otherwise entitled.  If 
you do participate, you are free to withdraw at any time.  Your decision to withdraw will 
involve no penalty or loss of benefits to which you are otherwise entitled. 
 
Your principle investigator, co-investigators, or student investigator can stop your 
involvement in the study at anytime without your consent. This could occur due to: 
1.) The investigators believe it to be necessary for your health or safety 
2.)  You failed to comply with study instructions 
3.)  Administrative reasons requiring your withdrawal 
 
 
QUESTIONS: 
If you have any questions about this study, contact: 
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Amy L. Throckmorton, Ph.D. 
Assistant Professor  
Department of Mechanical Engineering 
Virginia Commonwealth University 
VCU Box # 843015 
Office (804)-827-2278 
Fax (804)-827-7030 
althrock@vcu.edu 
 
 
William B. Moskowitz, M.D. 
Professor, Pediatrics and Medicine 
Interim Chair, Department of Pediatrics 
Chairman, Division of Pediatric Cardiology 
VCU/Medical College of Virginia  
VCU Box #980646 
Office (804)-828-9143 
wmoskowitz@mcvh-vcu.edu 
 
 
Scott D. Gullquist, M.D. 
Associate Professor, Pediatric Cardiology 
Department of Pediatrics 
VCU/Medical College of Virginia 
VCU Box #980646 
Office (804)-828-5745 
sgullquist@mcvh-vcu.edu 
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Sonya Bhavsar, B.S. 
Graduate Student Research Assistant 
Department of Mechanical Engineering 
Virginia Commonwealth University 
Mobile (540)-915-1248 
bhavsarss@vcu.edu 
 
 
If you have questions about your rights as a research subject, you may contact: 
 
Office of Research 
Virginia Commonwealth University 
800 East Leigh Street, Suite 113 
PO Box 980568 
Richmond, VA  23298 
(804) 827-2157 
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Do not sign this assent/consent form unless you have had a chance to ask questions 
and have received satisfactory answers to all of your questions.  Additional information 
about participation in research studies can be found at: 
http://www.research.vcu.edu/irb/volunteers.htm 
 
ASSENT for a patient between the ages of 7 and 12 
 
I agree to be in a study that uses MAS trousers (pants that inflate with air like a blood 
pressure cuff) to determine changes in blood flow to the heart. This study was explained to 
me by my parent/guardian and the doctor.  They said that I could be in it. The only people 
who will know about my results will be the people in charge of the study.  
 
In this study I will put on a pair of pants that inflate with air like blood pressure cuffs. I 
will be lying on my back. The doctor, nurses, and people in charge will be watching me 
closely to make sure I am ok during the study. The pants will inflate and squeeze lightly on 
both of my legs three times. It will only take about 20 minutes. If I ever feel 
uncomfortable, I will tell the doctor and he will stop the study.  
 
Writing my name below means that this page was read by me or to me and that I agree to 
be in this study. I know what will happen to me during the study. If I decide to quit the 
study, all I have to do is tell the person in charge.  
 
 
__________________________________________ __________________ 
Child's Signature                  Date 
 
 
________________________________________              
Name of Person Conducting Informed Assent                                                    
 
  
__________________________________________            __________________ 
Signature of Person Conducting Informed Assent                                    Date 
 
 
__________________________________________ __________________ 
Signature of Investigator (if different from above)                                            Date  
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ASSENT for a patient between the ages of 13 and 17 
 
“I have read the description of the study titled Clinical Measurement of Pressure 
Augmentation in the Systemic Venous Circulation using Medical Anti-Shock Trousers 
which is printed above.  I understand the procedures and what will happen to me in the 
study. I have received permission from my parent(s) to participate in the study, and I agree 
to participate in it. I know that I can quit the study at any time.” 
 
 
 
________________________________   ____________________ 
Signature of Child                                                                                                   Date 
 
 
CONSENT  
 
I have been provided with an opportunity to read this consent form carefully.  All of the 
questions that I wish to raise concerning this study have been answered.   
 
By signing this consent form, I have not waived any of the legal rights or benefits, to 
which I otherwise would be entitled.  My signature indicates that I freely consent to 
participate in this research study.  I will receive a copy of the consent form once I have 
agreed to participate. 
 
Please read if you are the Parent/Legal Guardian of a patient participating in this study:  
You are making the decision to allow your child to participate in this study. Your signature 
below indicates that you have read the information provided above and have decided to 
allow him or her to participate in this study. If your child is between the ages of 7 and 12, 
your signature below indicates that you have talked with your child about the study and 
believe he or she fully understands what will happen during the study. If you later decide 
that you wish to withdraw your permission for your child to participate in the study, simply 
tell an investigator or the doctor. You may discontinue his or her participation at any time. 
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________________________________________________ 
Subject Name, printed 
 
 
________________________________________________ ________________ 
Subject Signature                                                                                            Date 
       
 
_______________________________________________  
Name of Parent or Legal Guardian 
(Printed)    
 
 
_______________________________________________ ________________ 
Parent or Legal Guardian Signature      Date 
 
 
________________________________________________ 
Name of Person Conducting Informed Assent/Consent  
Discussion / Witness  
(Printed) 
 
________________________________________________ ________________ 
Signature of Person Conducting Informed Assent/Consent   Date 
Discussion / Witness  
 
 
________________________________________________ ________________ 
Investigator Signature (if different from above)                                       Date 
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VITA 
 
 
Sonya Sanat Bhavsar was born on January 13, 1986 in Trenton, New Jersey and is 
a citizen of the United States of America. She graduated from Hidden Valley High School 
in Roanoke, Virginia in 2004 and received her Bachelor of Science in Biomedical 
Engineering from Virginia Commonwealth University in Richmond, Virginia in 2008. 
During her undergraduate education Sonya worked as a research assistant at the Massey 
Cancer Center in the Molecular Cancer Therapeutics Programs in 2006 and the VCU/MCV 
Nursing School PRO Study in 2007.  
In the fall of 2008, Sonya entered her Masters program in Mechanical Engineering 
at Virginia Commonwealth University. She worked as a research assistant in the BioCirc 
Laboratory under the direction of Dr. Amy Throckmorton. Sonya also worked as a 
teaching assistant and part time as an Orthopedic Care Partner at the Medical College of 
Virginia. She served as the president of the Society of Women Engineers and founding 
member and president of American Society of Artificial Internal Organs:fyi student 
chapter. Sonya also volunteered her time to the community as an Emergency Medical 
Technician at Lakeside Volunteer Rescue Squad where she is the chief financial officer, 
board member, and squad leader.  
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During her graduate work, Sonya was honored as the recipient of the 2009 
Biomedical Engineering Graduate Student award at the 5th International Conference of 
Pediatric Mechanical Circulatory Support Systems and Pediatric Cardiopulmonary 
Perfusion Conference. She was also honored as a 2010 VCU I-GEEAR GAAN fellow and 
recipient of the 2010 Susan E. Kennedy Scholarship.  Sonya was co-author on several 
publications, professional conference presentations, and professional poster presentations 
including being first author on “Intravascular Mechanical Cavopulmonary Assistance for 
Patient with Failing Fontan Physiology”, “Interaction of an Idealized Cavopulmonary 
Circulation with Mechanical Circulatory Assist using an Intravascular Rotary Blood 
Pump”, “Use of External Pressure Application to Augment Fontan Hemodynamics”, and 
several others.  
 
 
  
